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1. INTRODUCTION 
1.1. In-cell NMR 
Structural Biology is a field of Life Sciences that determines and analyzes 
structural information of biological macromolecules at atomic level, in particular 
throughout techniques such as X-ray crystallography and nuclear magnetic 
resonance (NMR). Despite the fact that the majority of protein structures come 
from X-ray crystallography data, NMR is the technique of choice when it comes 
to study protein-protein interactions, folding, affinity constants, kinetics and 
thermodynamics in solution. The structural characterization is the first step to get 
towards functional information, relation and interaction with partners, 
physiological responses to environment changes or site-specific mutations. Most – 
if not all – intracellular proteins exert their function by interacting with specific 
partners. 
To date, the structural characterization of such interactions is mostly carried 
out with isolated proteins in vitro. Nowadays the interest of characterizing 
macromolecular functions inside the complex cellular environment is rising. To 
achieve this ambitious purpose, high resolution imaging and high-resolution 
structural tools are required. In the last fifteen years, in-cell NMR spectroscopy 
has been established as a method to investigate biological macromolecules in their 
physiological environment (Figure 1). In-cell NMR allows us to study several 
physiological processes such as protein folding [1], interactions with other 
proteins [2], metal ions binding [3], and drug screening [4]. The information 
obtained has a high biological significance, as the proteins are closer to their 
physiological conditions in terms of components present in the cell and of other 
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aspects such as pH, redox potential and macromolecular crowding.  
A first series of successful in-cell NMR applications relied initially on living 
E. coli cells to study macromolecular crowding, protein structure and folding, and 
interaction with other molecules such as proteins, drugs, nucleic acids, or other 
cellular components [5, 6]. More recently, the technique has been further extended 
to the investigation of eukaryotic proteins in eukaryotic cells, which could provide 
higher biological significance when studying structure and function [7]. Several 
methods rely on recombinant protein production in E. coli, followed by protein 
insertion inside eukaryotic cells. Different insertion techniques were developed 
such as microinjection [8] in oocytes, fusion with a cell-penetrating peptides [9], 
the use of pore-forming toxins [10] and protein electroporation [11, 12] in 
cultured cells. A conceptually different approach relies on transient protein 
expression directly in mammalian cells [13]. This approach is especially suited for 
monitoring protein folding and maturation events occurring right after protein 
synthesis [14] and to co-translationally deliver proteins to specific organelles, 
allowing in organello NMR approaches [15]. 
Furthermore, recent works showed that a protein structure (GB1 domain) 
Figure 1. Overview of the existing sample preparation approaches for in-cell NMR. A) isotopically labeled 
proteins can be expressed (green) in bacterial cells, yeast cells, insect and mammalian cells  by introducing an 
expression vector(s) encoding the protein(s) of interest; Isotopically enriched nutrients are provided after 
induction/transfection. B) purified labeled proteins (blue) can be delivered in X. laevis oocytes by microinjection 
or in human cells by CPP-mediated, or by permeabilizing the cells either with pore-forming toxins or via 
electroporation [6]. 
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could be resolved inside eukaryotic cells by in-cell NMR thanks to the 
introduction of a paramagnetic lanthanide-binding tag, which allowed measuring 
paramagnetic-based structural constraints, protein backbone PCSs and RDCs, in 
Xenopus laevis oocytes [16, 17]. 
In this PhD research work, I addressed a number of aspects both at 
methodological and at application level. We successfully applied solution in-cell 
NMR to investigate the redox-state of soluble disulfide-containing proteins inside 
different living systems (bacterial and human cells). We determined the protein 
redox-state distribution when cofactors or redox partners are supplied. We showed 
how in-cell NMR is a promising sensitive and direct technique for investigating 
protein redox distributions inside cells, exploitable also in addition or as a 
valuable alternative to GSH-fluorescence probes and chemical essays on cell 
extracts.  
Furthermore, we showed how in-cell NMR can shed light on the effects of 
potential drugs on a target protein within the cellular context. Such strategy will 
be beneficial for evaluating candidate drugs for treating neurodegenerative 
diseases, such as amyotrophic lateral sclerosis.  
When investigating proteins in the cellular context, many challenges arise, as 
a consequence of its intrinsic complexity. In particular, to increase the 
opportunities of in-cell NMR applications, practical limitations need to be 
overcome: on one hand sample preparation issues must be addressed to ensure 
that the physiological conditions of macromolecules inside the living cells are 
maintained during the measurements (cell viability and stability over time, proper 
amount of oxygen and nutrients, Temperature, pH); on the other hand, although 
there have been considerable advances in the sensitivity of the NMR technique 
throughout consistent hardware improvements, the short sample lifetime still 
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imposes limits on the type and length of the NMR experiments that can be 
recorded.  
To widen the range of in-cell NMR applications and to overcome some of the 
practical limitations from a sample preparation perspective, our primary focus has 
been to enable the detection of intracellular soluble proteins that are not detectable 
with canonical solution NMR experiments. Within the cells, complex phenomena 
such as intermolecular interactions take place that might affect the relaxation 
properties of proteins. In particular, specific and nonspecific interactions with 
other cellular components can increase the rotational correlation time and cause 
line broadening beyond detection. Such protein-specific effects are therefore a 
limiting factor for in-cell NMR in solution. Cellular solid-state NMR in principle 
has the chance to overcome such limitations allowing the characterization of 
proteins involved in molecular complexes in the cellular environment [18].  
In parallel, we sought to expand the existing solution in-cell NMR methods 
to study protein-protein interactions with atomic detail in living cells. To this aim, 
our strategy relied on the combination of DNA transfection with protein delivery 
techniques in order to maximize protein labeling selectivity inside the cells and 
minimizing cellular background signals in the NMR spectra. Among the various 
protein mediated delivery techniques suitable for in cell NMR sample preparation, 
we focused on protein electroporation, which has several advantages: it does not 
require specific protein modifying targeting sequences (such as cell-penetrating 
peptides) and it does not imply any cell treatment with toxic and harmful 
compounds (such as pore-forming toxins). 
1.2. Cellular redox systems and oxidative stress 
Sulfur is among the six most abundant elements in Life. Indeed it is present in 
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many cellular components, such as small metabolites and proteins. Thanks to its 
chemical reactivity, sulfur is strongly involved in the redox biochemistry of living 
organisms. In proteins, methionine and cysteine are the only amino acid that can 
undergo reversible oxidation in a biological environment. In particular, the thiol 
group (-SH) of cysteine is the main character of many oxidative reactions and 
modifications that are involved in gene regulation, signalling and protein function 
[19,20]. A change in the redox state of thiol/disulfide couples affect protein 
conformation [21], transporter activity, enzymatic activity, ligand binding [22], 
protein-protein interactions, protein trafficking, protein-DNA interactions [23], 
and protein degradation. 
In order to maintain physiological conditions, redox homeostasis plays a key 
role, from bioenergetics to functional processes and metabolism, and it is 
controlled by sophisticated oxidation-reduction processes. Like most biological 
processes, intracellular redox reactions do not reach the thermodynamic 
equilibrium but are kept in non-equilibrium steady states [24]. Whenever in a cell 
there is an imbalance between redox systems operating concurrently, deviations 
from physiological conditions arise, which are often linked to the insurgence of 
pathologies. In particular, oxidative stress has been linked to a high intracellular 
levels of aerobic metabolism products that cause damage. A wide definition of 
oxidative stress is “an imbalance between oxidants and antioxidants in a cell, in 
favor of the oxidants” [25]. A large number of oxidants is represented by reactive 
oxygen species (ROS), which cover a variety of radicals derived from oxygen 
such as the superoxide anion O2
-2
, hydroxyl (HO
•
), peroxyl (RO2
•
) and alkoxyl 
radicals (RO
•
), as well as non radical species such as hydrogen peroxide (H2O2). 
In addition to ROS, reactive nitrogen species (RNS), reactive sulfur species (RSS) 
and reactive carbonyl species (RCS) also have notable effects on redox biology 
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and oxidative stress [26, 27]. 
Despite the large amount of knowledge, the current understanding of the 
mechanisms of ROS-induced toxicity is still incomplete. There are studies 
showing that some ROS can act as signaling molecules promoting physiological 
functions, high level of ROS show evidences of promoting irreversible oxidative 
changes of DNA, lipid and proteins, promote protein disfunction, trigger cell 
death [28], regulate signaling pathways [29], and are involved in tumor 
progression [30]. 
As a defense against ROS, cells have developed several antioxidant systems 
[31, 32]. Eukaryotic cells have several ways to protect themselves from oxidative 
damage: the glutathione system, superoxide dismutase, the 
thioredoxin/peroxiredoxin system and catalase.  
Oxidative stress has also been associated with the onset of long-term 
neurodegenerative diseases such as Alzheimer disease, Parkinson disease and 
multiple sclerosis. Among them, Amyotrophic Lateral Sclerosis (ALS) is a fatal 
degenerative disease that cause the death of motor neurons [REF 33]. Several 
variants of ALS are known, which have been associated to different genes. 
Despite the large amount of knowledge, the pathogenesis of ALS is not yet fully 
understood. A subset of ALS cases, both sporadic and familial, are linked to the 
antioxidant enzyme superoxide dismutase 1 (SOD1) The hallmark of SOD-linked 
ALS is a toxic gain-of-function, which causes the misfolding and aggregation of 
SOD1 within motor neurons. Indeed, several mutations of the SOD1 gene have 
been identified in familial-ALS patients, which impair SOD1 folding and/or 
maturation and ultimately lead to its aggregation. 
1.2.1. The glutathione system 
The tripeptide glutathione (GSH, reduced form, and GSSG, oxidized form) is the 
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most abundant thiol-containing molecule inside cells. It has indeed a crucial role 
in redox homeostasis and in maintaining the proper intracellular redox 
environment for optimal cellular protein functions. Both GSH and proteins exert 
their thiol redox reactivity throughout the amino acid cysteine, that can undergo 
reversible thiol oxidation forming a disulfide bond. GSH is one of the molecules 
that mitigates the effects of ROS by reacting with disulfide bonds of cytoplasmic 
proteins, reducing them to cysteines and producing glutathione disulfide (GSSG). 
However, such process does not occur spontaneously and need enzymatic 
regulation [34]. The glutathione system includes GSH, glutathione reductase, 
glutathione peroxidases (GPX) and glutathione S-transferases (GST). Glutathione 
peroxidases (GPX) catalyze the decomposition of hydrogen peroxide and organic 
hydroperoxides. Glutathione reductase reduces GSSG and restores the GSH pool. 
Glutathione S-transferases are detoxification enzymes that catalyze the 
conjugation of GSH to a variety of exogenous and endogenous electrophilic 
compounds [35]. 
GSH is present in all cellular compartments, including the cytosol, the 
mitochondria, the nucleus and the endoplasmic reticulum, and acts as a distinct 
redox pool in each. Due to its high abundance, the redox couple GSH/GSSG is 
considered to be the primary cellular redox buffer, hence its redox potential is 
often used as an indicator for the redox environment of the cell [36]. 
The intracellular environment is generally reducing with respect to the 
extracellular environment. However, inside a cell the redox status is compartment-
dependent: the endoplasmic reticulum (ER), the Golgi apparatus and the 
mitochondrial intermembrane space (IMS) have a less reducing environment 
compared to the one found in the cytoplasm and the nucleus [37]. Typically, this 
difference in the redox pool is reflected by the higher abundance of disulfide 
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bonds found in proteins of the ER/Golgi and of the IMS, compared to cytosolic 
proteins. 
1.2.2. The thioredoxin system 
In cells there are two main pathways in charge of keeping the protein thiols 
reduced: the thioredoxin-thioredoxin reductase pathway and the glutaredoxin-
glutathione reductase one, which are both linked to NADPH as electron donor. 
Thioredoxins are ubiquitous enzymes in all living organisms, which exert a 
central role in many physiological functions such as thiol-based redox system 
catalysis [38], iron-sulfur proteins biogenesis [39], redox sensing and redox 
environment maintenance and antioxidant activity [40]. 
Thioredoxins (Trx) are small proteins that share a common folding, the so 
called ‘thioredoxin fold’ constituted by a barrel core of five β-strands surrounded 
by four α-helices; their active site contains a highly conserved cysteines pattern, 
usually a CXXC motif, that is cycled between an active (reduced) dithiol form and 
an oxidized disulfide form [41]. In its active state, thioredoxin scavenges reactive 
oxygen species and keeps proteins in their reduced state [42]. 
Like GSH in mammalian cells, members of the thioredoxin family are 
compartmentalized: inside the cytosol there are thioredoxin 1 (Trx1) and 
glutaredoxin 1 (Grx1), that interact with copious cytosolic substrates and catalyze 
protein dithiol/disulfide exchange reactions. The mechanism through which Trx1 
interacts with its substrates consists in the reduction of the protein-protein 
disulfide bond throughout a dithiol reaction ending up in a intramolecular 
disulfide bond formation between the two thiols of the active site. Thioredoxin 
reductase restores reduced Trx1 through reducing equivalents provided by 
NADPH [43]. Grx1 instead has a highly specificity for glutathione and has a 
stronger tendency to reduce glutathionylated proteins. The mechanism of 
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reduction relies on a thiol-disulfide exchange mechanism resulting in the 
formation of glutathionylated Grx1 intermediate, regenerated to reduced Grx1 by 
GSH forming GSSG. In turn, glutathione reductase catalyzes GSSG reduction to 2 
GSH through NADPH. 
Among the various partners, Grx1 and Trx1 play a key role in keeping 
reduced some mitochondrial CHCH proteins while they are synthesized inside the 
cytoplasm so that they can translocate inside the intermembrane mitochondrial 
space [44, 45]. 
1.2.3. Superoxide dismutase 
Superoxide dismutases (SODs) are metalloenzymes which catalyze the 
disproportionation of superoxide anion to oxygen and hydrogen peroxide: 
(2 O2
-2
 + 2 H
+
  O2 + H2O2) 
Superoxide dismutases ubiquitously exist in eukaryotes and prokaryotes. Different 
SOD enzymes exist, located in different cellular compartments, and rely on metal 
ions such as copper (Cu
2+
), manganese (Mn
2+
) or iron (Fe
2+
) as cofactors. Copper-
zinc superoxide dismutase 1 (SOD1) is a 32 kDa homo-dimer where each 
monomer is a folded greek-key β-barrel. SOD1 is ubiquitously expressed in all 
eukaryotic cells, and it is present at high concentration inside the cytoplasm, as 
well as inside the mitochondrial intermembrane space (IMS). It also translocates 
into the nucleus as a response to oxidative stress [46]. To reach the functional 
form and exert the catalytic activity, SOD1 needs to undergo a series of 
maturation events: dimerization, zinc and copper binding, and the formation of an 
intramolecular disulfide bond. In the case of human SOD1, two activation 
pathways have been identified to date: one requiring the copper chaperone for 
SOD1 (CCS) to bring copper and activate SOD1 through oxidation and one that 
works independently from CCS. The SOD1 maturation pathway has been 
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recapitulated in cultured human cells with atomic resolution by in-cell NMR [47]. 
In human cells, zinc binding occurs spontaneously, while copper-binding and 
disulfide formation occur when CCS is co-expressed together with SOD1, 
suggesting that increased levels of CCS are required to efficiently deliver copper 
to SOD1 when the latter is overexpressed, and for disulfide-bond formation [48]. 
CCS could promote disulfide formation even in the absence of copper, suggesting 
an alternative copper-independent mechanism for the oxidation of SOD1 cysteines 
[45]. 
Mutations in the hSOD1 gene have been associated to a familial form of 
Amyotrophic Lateral Sclerosis (fALS), a progressive debilitating 
neurodegenerative disease consisting in a selective progressive loss of motor 
neurons (primary motor cortex, brain stem and spinal), causing a progressive 
muscle atrophy, spasticity, paralysis and ultimately death. To date, more than 150 
familial fALS-linked sequence mutations have been reported [49]. Most of these 
mutations do not affect SOD1 enzymatic function. Instead, the pathogenic activity 
of SOD1 mutants stems from a gain of toxic function, which is correlated to the 
formation of aberrant SOD1 oligomers or fibrillar aggregates. Still, the exact 
mechanism of SOD1-linked fALS pathogenesis remains unclear [50, 51, 52]. 
Notably, these mutations have been shown not to be strictly necessary for 
triggering toxic aggregation of SOD1 [53]. Indeed, wild-type SOD1 has been 
shown to have a similar toxic gain of function due to a fibrillation behavior 
analogous to SOD1 mutants [54]. In particular, it has been shown that the metal-
binding deficiency and the reduced disulfide bond promote structural instability 
and protein aggregation, also for wild-type SOD1 [55, 56, 57]. Therefore, 
understanding which factors negatively affect the SOD1 maturation pathway 
within a cell is critical to develop novel fALS therapeutic strategies. 
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2. RESULTS 
2.1. Direct structural evidence of protein redox regulation 
obtained by in-cell NMR 
In-cell NMR analysis was applied to study the folding and to the redox state of 
three human proteins in the cytoplasm of human and bacterial cells. These are two 
small proteins of the mitochondrial IMS, human Cox17 and Mia40, which are 
encoded by nuclear DNA and therefore are present in the cytoplasm before they 
enter mitochondria. The redox state of human SOD1 was also investigated. 
Through in-cell NMR we can probe directly the structural properties of the 
proteins in different redox states in each cellular environments. Thanks to these 
structural information, we could determine the distribution of proteins redox 
states, which was then compared to the one predicted from the midpoint reduction 
potential, assuming the thermodynamic equilibrium with GSH. In human cells, 
the distributions were not at the equilibrium, while co-expression of redox-
regulating protein partners of Cox17 and Mia40 (Grx1 and Trx1) shifted their 
distributions closer to the equilibrium. In bacterial cells (BL21) the proteins were 
mostly reduced, despite the less reducing cellular environment, while in the 
absence of the disulfide reduction pathways (in Origami B cells) the oxidized state 
of each protein was observed despite the predicted E
°'
. These results show that in-
cell NMR is a suitable method to directly observe the redox state of a soluble 
disulfide-containing protein. They also showed that the oxidation state of some 
proteins is controlled by specific proteins and pathways, which are not directly 
linked to the GSH pool, as is the case for the SOD1-CCS pathway. 
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2.2. The antioxidant molecule ebselen rescues the toxic 
characteristics of mutant SOD1  
 
Oxidative stress has been linked to a countless amount of pathologies, including 
ALS and asthma. The main pathological hallmark of ALS is the formation of 
protein aggregates mainly in degenerating motor neurons and surrounding 
oligodendrocytes [58]. About 20% of familial ALS cases are caused by mutations 
in the hSOD1 gene. There are evidences that mutated SOD1 can form cytotoxic 
protein aggregates alone or with other proteins that possibly lead to a loss of the 
enzymatic function or to acquiring toxic properties [59]. In this work, we studied 
the interaction of the small antioxidant molecule ebselen with disease-related 
SOD1 mutants. Intrestingly we found that in cells ebselen restores the correct 
folding of destabilized SOD1 mutants by promoting disulfide formation and zinc 
binding. In vitro, ebselen was found to covalently bind SOD1 near the dimer 
interface, thereby restoring the strength of dimerization towards the proper 
maturation pathway. Ebselen, therefore, contributes to restore SOD1 physiological 
maturation and prevents its unfolding and aggregation. In addition to its already 
known anti-inflammatory pharmacological properties, ebselen could be exploited 
as a drug precursor for translation into the clinical trials. 
 
21 
 (Submitted) 
The antioxidant molecule ebselen rescues the 
toxic characteristics of mutant SOD1 
Michael J. Capper
1
, Gareth S. A. Wright
1
, Letizia Barbieri
2,3
, Enrico 
Luchinat
2,4
, Eleonora Mercatelli
2
, Luke McAlary
5
, Justin J. Yerbury
6
, Paul 
M. O’Neill7, Svetlana V. Antonyuk1, Lucia Banci2,8, S. Samar Hasnain1 
Affiliations 
1. Molecular Biophysics Group, Institute of Integrative Biology, Faculty of 
Health and Life Sciences, University of Liverpool, L69 7ZB UK. 
2. Magnetic Resonance Centre (CERM), University of Florence, 50019 Sesto 
Fiorentino, Italy. 
3. Interuniversity Consortium for Magnetic Resonance of Metallo Proteins 
(CIRMMP), 50019 Sesto Fiorentino, Italy. 
4. Department of Biomedical, Clinical and Experimental Sciences, University of 
Florence, 50134 Florence, Italy. 
5. Department of Physics & Astronomy, University of British Columbia, 
Vancouver, British Columbia, Canada. 
6. llawarra Health and Medical Research Institute, University of Wollongong, 
Wollongong, Australia. 
7. Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD UK. 
8. Department of Chemistry, University of Florence, 50019 Sesto Fiorentino, 
Florence, Italy. 
  
22 
The antioxidant molecule ebselen rescues the toxic characteristics of mutant SOD1 
 
Michael J. Capper
1*
, Gareth S. A. Wright
1*
, Letizia Barbieri
2,3*
, Enrico Luchinat
2,4*
, 
Eleonora Mercatelli
2
, Luke McAlary
5
, Justin J. Yerbury
6, Paul M. O’Neill7, Svetlana V. 
Antonyuk
1
, Lucia Banci
2,8,§
, S. Samar Hasnain
1,§
. 
* These authors contributed equally, § Corresponding authors 
 
1. Molecular Biophysics Group, Institute of Integrative Biology, Faculty of Health and 
Life Sciences, University of Liverpool, L69 7ZB UK. 
2. Magnetic Resonance Centre (CERM), University of Florence, 50019 Sesto 
Fiorentino, Italy. 
3. Interuniversity Consortium for Magnetic Resonance of Metallo Proteins (CIRMMP), 
50019 Sesto Fiorentino, Italy. 
4. Department of Biomedical, Clinical and Experimental Sciences, University of 
Florence, 50134 Florence, Italy. 
5. Department of Physics & Astronomy, University of British Columbia, Vancouver, 
British Columbia, Canada. 
6. llawarra Health and Medical Research Institute, University of Wollongong, 
Wollongong, Australia. 
7. Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD UK. 
8. Department of Chemistry, University of Florence, 50019 Sesto Fiorentino, Florence, 
Italy. 
 
Significance Statement 
Chronic lung and neurodegenerative diseases are not often causally linked. However 
oxidative stress and the propensity for the antioxidant protein SOD1 to become 
disulphide reduced are common to asthma and amyotrophic lateral sclerosis. Here we 
show that ebselen, a small molecule which is known to combat oxidative stress, can 
change the molecular characteristics of SOD1 associated with disease through a direct 
interaction. Ebselen promotes SOD1 disulphide bonding, zinc binding and folding. It can 
also covalently attach to SOD1 at the dimer interface and restore the strength of 
dimerization. Ebselen’s direct and indirect pharmacological properties mark it as very 
good candidate for translation into the clinic. 
 
Key words: Small molecules; neurodegenerative disease; asthma; oxidative stress. 
 
Abstract 
Superoxide dismutase-1 (SOD1) is an important part of human oxidative stress defence 
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but point mutations in its primary sequence cause the neurodegenerative disease (ND) 
amyotrophic lateral sclerosis (ALS). ALS mutations reduce the ability of SOD1 to fold, 
metalate, dimerize and form an intra-subunit disulphide bond. Ultimately this leads to 
neuronal death through the accumulation of large insoluble aggregates or small 
oligomers. Loss of the disulphide bond from wild-type SOD1 is also seen in asthma 
where dismutase activity is decreased as a result. The role of oxidative stress in the 
pathogenesis of ND prompted us to investigate the small molecule antioxidant compound, 
ebselen, and its effect on the molecular characteristics of SOD1 associated with ALS and 
asthma. Within the cell, ebselen very efficiently catalyzes SOD1 intra-subunit disulphide 
bond formation through a selenylsulphide/selenol-thiol exchange mechanism. This directs 
correct SOD1 folding and zinc binding which depopulates the globally unfolded 
precursor associated with mutant SOD1 toxicity. Aggregate formation and the propensity 
of mutant SOD1 for premature degradation are diminished as a result. This demonstrates 
that exogenous promotion of SOD1 disulphide bonding is a viable therapeutic approach 
for ALS. In less reducing environments, ebselen forms a selenylsulphide bond with 
Cys111 and restores the monomer-dimer equilibrium of A4V SOD1 to wild-type through 
non-covalent reinforcement of the dimer interface. Ebselen is therefore a potent, bi-modal 
SOD1 pharmacological chaperone which combines properties of the copper chaperone 
for SOD1 and the antioxidant edaravone, which recently became only the second ALS 
therapeutic to be licenced in the United States. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal motor system neurodegenerative disease. 
Mutations to the superoxide dismutase-1 gene were the first identified genetic link with 
ALS (1). Histopathology on tissues from humans and mutant superoxide dismutase-1 
(SOD1) animal models has shown how SOD1 protein accumulates in Lewy-like bodies 
within the cytoplasm and the mitochondria of motor neurons and support cells. These 
insoluble inclusions are replete with misfolded SOD1 which has not been cleared by the 
protein degradation pathways (2). 
 
Pioneering work on the catalytic activity of SOD1 and subsequent exploration of its 
structure proved that a host of post-translational modifications are necessary for stability 
and function (3). While zinc binding and an intra-subunit disulphide are not directly 
involved in catalysis they hold the molecule’s tertiary and quaternary structure (4–6). 
ALS-related mutations reduce the ability of SOD1 to bind necessary metal cofactors and 
predispose it to disulphide reduction. Activity loss through disulphide bond reduction is 
also characteristic of SOD1 in asthma sufferers where elevation of intracellular reduced 
glutathione increases the reduction potential of the cytoplasm (7, 8). In ALS, an inability 
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to undergo these post-translational modifications shifts the oligomer equilibria in favour 
of the monomer and a portion of cellular SOD1 is forced to reside in a persistently 
misfolded state (9, 10). Exposure of normally internalized hydrophobic motifs leads to 
aberrant oligomerization which manifests as disulphide reduced, metal-free, insoluble 
SOD1 inclusions in cell and animal models (11, 12). In a corollary with -amyloid 
accumulation in Alzheimer’s Disease, it seems that non-native SOD1 monomers or small 
oligomers are the toxic species rather than large insoluble amyloid fibrils (13). 
Crystallographic structures have shown how these toxic seeds can be assembled (14, 15). 
The unfolding and aggregation propensity of SOD1 have been shown to correlate with 
life expectancy, post-diagnosis in humans and transgenic mouse models (9, 16–18). 
Consequentially, promoting normal folding and post-translational modification has the 
potential to divert mutant SOD1 away from the toxic pathway and, at the very least, 
extend the disease’s clinical duration. Non-covalent ligand interactions have been 
demonstrated on the SOD1 -barrel surface but each failed to change mutant thermal 
stability or inhibit aggregation in vitro possibly due to low binding affinity (19). 
Conversely, addition of cisplatin to the reactive Cys111 residues or covalently cross-
linking them across the dimer interface groove with bis-maleimide analogues have been 
proven to modulate disease related characteristics. Both bismaleimidoethane (BMOE) 
and cisplatin increase SOD1 thermal stability, while the latter also inhibits in vitro and in-
cell aggregation (20, 21). However, both interactions have been shown to inhibit 
heterodimer formation with the copper chaperone for SOD1 (hCCS) (22). 
 
Ebselen is an organoselenium compound with broad antioxidant properties (23). It is also 
an anti-inflammatory and has been tested as a treatment for a variety of illnesses 
including stroke (24), bipolar disorder (25) and aneurysmal subarachnoid haemorrhage 
(26). It is well tolerated in humans can be formulated for oral administration and is 
neuroprotective. Interestingly, it has also been shown to reduce the cytotoxic burden of 
mutant SOD1 mitochondrial pathology (27). Ebselen has strong pharmacological and 
structural similarities with edaravone, which very recently became only the second drug 
licensed for the treatment of ALS in the United States. Both drugs are antioxidants and 
have been used in the treatment of stroke.  
 
Here we demonstrate that ebselen and its analogue ebsulphur bind to SOD1 at the Cys111 
site in vitro. This interaction shifts the SOD1 monomer-dimer equilibrium in favour of the 
dimer and returns the affinity of the A4V dimer to that of wild-type. This occurs without 
covalent tethering of monomer subunits within the SOD1 dimer. Importantly the 
increased dimer stability does not prevent heterodimer formation with hCCS. This proof 
of principle is important as Cys111 targeted drug compounds could bind the free 
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sulphydryl of both mutant or wild-type SOD1 and should not prevent hCCS catalysed 
activation. Furthermore, we show by in-cell and in vitro NMR that ebselen reacts with 
disulphide-reduced SOD1 in the human cell cytosol causing formation of the intra-
subunit disulphide bond. In doing so, it promotes correct SOD1 folding and zinc binding. 
Directing the nascent protein down the correct post-translational modification pathway 
prevents accumulation of unfolded species, thought to be the precursor of mutant SOD1 
toxicity, premature degradation and formation of insoluble aggregates (9, 10). Thus, 
Ebselen rescues the toxic characteristics of mutant SOD1 through two independent 
disulphide formation and dimer stabilization mechanisms deployment of which is 
dependent on the nature of the environment. Ebselen’s on-target SOD1 pharmacological 
chaperone activity, in combination with its usage history and positive secondary 
pharmacology reminiscent of edaravone, indicate it is a very promising lead not only in 
the search for therapeutics which can modulate pathogenic SOD1 behaviour in ALS, but 
also, asthma.  
 
 
Results 
 
Ebselen and ebsulphur form a covalent bond with SOD1 at Cys111 
Screening libraries of existing drugs, those that are no longer used or drugs that were not 
successful in the final stages of clinical trials, is an increasingly popular approach for 
therapeutic discovery. Drug repurposing offers a cheaper and faster route through early 
clinical trials as ADMET information is available, creating a major advantage for ‘orphan 
diseases’ such as ALS. This approach has resulted in historic as well as recent successes 
(see review (28)), including the licensing of edaravone in Japan and the US to slow ALS 
progression (29). Given the susceptibility of Cys111 to oxidative modifications in SOD1-
ALS and previous work on cisplatin and BMOE we undertook a crystallographic screen 
of a small library of cysteine-reactive compounds known to have favourable antioxidant 
properties (Supplementary Fig. 1). Ebselen and ebsulphur were found to bind SOD1 
Cys111 while derivatives with a benzyl substitution on the benzoisoselenazole or 
benzoisothiazolone nitrogen did not, possibly due to altered reactivity or steric hindrance 
in the dimer groove. 
 
The  .  and  .   Å resolution structures of wild-type, zinc metalated, disulphide intact 
SOD1 bound to ebselen or ebsulphur allowed for the unambiguous placement of the 
compounds in the SOD1 dimer groove (Fig. 1A and B). They show the formation of a 
selenylsulphide or mixed disulphide covalent bond, respectively, between ligand and 
Cys111 created by nucleophilic attack of the free Cys111 sulphydryl at the electrophilic 
Se-N and S-N centres contained within each respective heterocycle. Electron density is 
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clear for both ligands except for a small part of one of the ebsulphur phenyl rings which 
projects into solvent. This indicates some rotational freedom in this group (Figs. 1C and 
D). No ligand conjugation was observed at Cys6 and the intramolecular disulphide bond 
between Cys57 and Cys146 remained intact. No large structural changes were seen 
between the amino acid backbone or side chains of ebselen-conjugated SOD1 compared 
to unbound SOD1 crystallized under the same conditions (RMSD 0.242 Å, 
Supplementary Fig. 2). Ebselen and ebsulphur form tight interactions within the SOD1 
dimer groove and a hydrogen bond is formed between the ligand carbonyl and a highly 
coordinated water molecule situated, on average, 2.55 Å away. Through this bond, the 
ligand is integrated into the crystallographic water network forming an indirect link to the 
Gly108 backbone amide of one SOD1 monomer. This reflects the asymmetry of ligand 
binding to each monomer. Ebselen and ebsulphur form an additional inter-dimer contact 
through planar stacking of their benzylamine groups. Analysis of the four dimer interface 
hydrogen bonds which contribute to SOD1 dimer affinity indicates bond shortening. The 
hydrogen bond between Gly51 N and Ile151 O is reduced from 2.81 Å in the atomic 
resolution model of SOD1 (PDB ID 2V0A) to 2.74 and 2.72 Å in the ebselen and 
ebsulphur models. The bond between Gly114O and Ile151N is also reduced, from 2.92 Å 
to 2.78 Å and 2.83 Å. Ile151 is located just 3.8 Å away from ebselen in chain A 
(Supplementary Fig. 3). 
 
Ebselen and ebsulphur potentiate SOD1 dimer formation without hindering 
complex formation between SOD1 and hCCS 
The propensity for mutant SOD1 to exist as a monomer is a key contributory factor in the 
pathology of SOD1-ALS. Indeed, preventing dimer dissociation has been shown to 
increase SOD1 thermal stability and inhibit aggregation in vitro (20, 30). Native mass 
spectrometry (MS) preserves non-covalent interactions and allows quantification of tight 
homo-oligomer dissociation constants without reverting to chaotropic unfolding as well 
as the ability to resolve differentially modified protein species (Supplementary Fig. 4) 
(18, 31). As such we determined the effect of ebselen and ebsulphur on the SOD1 
monomer-dimer equilibrium. Wild-type zinc metalated, disulphide intact SOD1 was 
found to have a dimer dissociation constant (Kd) of 24  4 nM and the strength of 
dimerization is increased slightly by the addition of ebselen and ebsulphur (Fig. 2A). A4V 
SOD1, which leads to an highly aggressive form of ALS, has a much weakened dimer 
interaction resulting in partial monomerization at low micromolar concentrations (30). 
This is reflected in an increased dimer Kd, 957  30 nM. However, ebselen and ebsulphur 
completely restore dimer affinity to a wild-type level, Kd 16  3 and 23  4 nM 
respectively (Fig. 2A). A strengthening of the dimer interaction is also observed for ALS 
mutants G93A and I149T (Fig. 2A). The H46R/H48Q SOD1 artificial copper site mutant 
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displays caricature disease-related characteristics including a very strong propensity to 
exist in the disulphide reduced state and weakened affinity for zinc(32) that leads to 
complete monomerization at micromolar concentrations (Supplementary Fig. 5). Even in 
this extreme case, ebselen increases the strength of the dimer, Kd, 5.3  0.4 µM to 220  
27 nM, with ebsulphur having a similar but less pronounced effect (Fig. 2A). Overall, 
mutant SOD1 shows better dimer stabilization when bound to ebselen than ebsulphur and 
A4V SOD1 benefitted from the largest stabilization; a 60-fold increase (Fig. 2B). 
 
The copper chaperone for SOD1 (hCCS) is an important part of the cellular machinery 
that prepares SOD1 for its role in oxidant defence. Modifications to Cys111 that promote 
SOD1 thermal stability have previously been shown to prevent heterodimer formation 
between hCCS and SOD1, thus preventing hCCS-catalysed SOD1 copper acquisition and 
disulphide formation (22). In contrast to BMOE and cisplatin, and despite increasing the 
dimer affinity of SOD1, ebselen does not hinder complex formation between SOD1 and 
hCCS; the heterodimer readily forms under normal conditions (Fig. 3). 
 
Ebselen promotes formation of the SOD1 intra-subunit disulphide bond in living 
cells 
To determine whether ebselen exerts a protective role against SOD1 in the cytosol, its 
effect on intracellular SOD1 maturation was investigated in live human cells by in-cell 
NMR (33, 34). The pathway leading to SOD1 maturation has been recently recapitulated 
through in-cell NMR studies (35, 36). Beginning with monomeric, disulphide-reduced 
apo-SOD1, zinc binding occurs spontaneously leading to the formation of reduced E,Zn-
SOD1. Copper binding and disulphide bond formation occur subsequently, upon 
interaction with hCCS (36, 37). Disulphide-reduced E,Zn-SOD1 becomes a stable 
intermediate species in the cytosol if hCCS is not present in sufficient amount (38). In 
human cells treated with ebselen, intracellular E,Zn-SOD1 was fully oxidized, showing 
that ebselen efficiently promotes the formation of the SOD1 intramolecular disulphide 
bond (between Cys57 and Cys146). In contrast, >95% of the total E,Zn-SOD1 is found in 
the disulphide reduced state in untreated cells (Fig. 4A). This effect could be reproduced 
in vitro by treating reduced E,Zn-SOD1 with 1 equivalent per monomer of ebselen in an 
anaerobic environment (Fig. 4B), indicating that a redox reaction occurs directly between 
ebselen and the reduced Cys57 and Cys146 of SOD1. This mechanism is consistent with 
the known thiol oxidase activity of ebselen (39) and would function through the 
formation of a transient selenylsuphide bond which is then rearranged by selenyl-thiol 
exchange to yield the SOD1 disulphide and free ebselen selenol (2-hydroseleno-N-
phenylbenzamide). Interestingly, the ebselen selenol is a potent reducer of hydrogen 
peroxide and the ultimate product of this reaction is ebselen (40). Increased oxidative 
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stress could therefore promote ebselen recycling. 
 
Ebselen was not found to stably bind Cys111 of either disulphide oxidized or reduced 
SOD1 within the cytosol (Supplementary Figs. 6A and B) likely due to reduction of the 
selenylsulphide bond by glutathione, free cysteine or other cellular thiols. This was 
verified in vitro; treatment of ebselen-SOD1 with thiols at low concentrations (1 mM 
glutathione or dithiothreitol) at neutral pH resulted in the complete loss of conjugation 
(Supplementary Fig. 6C). 
 
Ebselen very effectively stabilizes mutant SOD1 in living cells 
Several ALS-linked SOD1 mutants fail to bind zinc in the human cytosol, and accumulate 
as unstructured species that may act as precursors in the pathogenic aggregation of SOD1 
(9, 10). Given that the intramolecular disulphide bond is known to increase the structural 
stability of wild-type and mutant SOD1, we reasoned that the oxidizing effect of ebselen 
could stabilize intracellular SOD1 mutants. Indeed, treatment with ebselen caused the 
oxidation of ALS-linked SOD1 mutants G93A and A4V in human living cells, and 
efficiently stabilized both proteins. This striking effect is evident when comparing the 
NMR spectra of treated and untreated cells (Fig. 5A and B). In cells treated with ebselen, 
disulphide intact E,Zn-SOD1 is detected at levels comparable to those of wild-type 
SOD1, whereas in untreated cells the SOD1 mutants are either largely accumulated as 
unfolded species (G93A, see Fig. 5A) or barely detected (A4V, possibly due to severe 
aggregation or degradation, see Fig. 5B). This stabilizing effect was further confirmed by 
western blot analysis of cell lysates, where the expression level of SOD1 mutants was 
markedly increased upon treatment with ebselen (Fig. 5C). Overall, these data indicate 
that the action of ebselen in stabilizing intracellular SOD1 occurs through a thiol 
exchange mechanism similar to that deployed by hCCS. The two modes of action 
targeting disulphide intact and disulphide reduced SOD1 (Fig. 6) are however not 
mutually exclusive and both could be exploited in future drug developments against ALS. 
 
Discussion 
Cellular oxidative stress is a common theme in the pathogenesis of neurodegenerative and 
lung inflammation diseases (41–43). In both asthma and ALS, the antioxidant SOD1 is 
found to be disulphide reduced. Dimerization, disulphide bond formation and metal ion 
acquisition are the canonical SOD1 post-translation modification (PTMs) steps on route 
to forming a stable and active enzyme (4–6). Each PTM contributes to both stability and 
activity. The inability of ALS-related SOD1 mutants to complete these steps is the central 
tenet of SOD1 pathogenesis dogma. This appears to extend to the bronchial inflammation 
disease asthma, where wild-type SOD1 is found to be disulphide is reduced as a result of 
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an imbalanced oxidized/reduced glutathione ratio. SOD1 dismutase activity is reduced as 
a result in both ALS and asthma however in ALS SOD1 accumulates into amorphous and 
fibrillar aggregates within the cytoplasm and mitochondria of neurons and astroglia (11, 
12, 44). Here we have shown that ebselen has astonishing capacities for correcting several 
aspects of aberrant SOD1 maturation with implications for the treatment of ALS and 
asthma. 
 
We have quantified the dimer dissociation constants of wild-type SOD1, and several 
disease related mutants, in non-denaturing conditions using native MS. While A4V and 
the artificial copper site mutant H46R/H48Q have a 40-fold and 220-fold reduction in 
their ability to form a dimer respectively, G93A and I149T have wild-type-like dimer 
interactions. This highlights the likelihood that SOD1 monomerization acts in concert 
with reduced copper or zinc affinity, thermal instability and local or global unfolding as 
the toxic cue. Using a combination of protein crystallography and native MS we have 
determined both the binding site and pose of two novel ligands, directly quantifying their 
effect on SOD1 dimerization and predicting their mode of action. We conclude that 
ebselen binding to Cys111 restores the dimer affinity of A4V SOD1 to that of wild-type. 
The effect is mediated by - stacking between ebselen or ebsulphur aromatic rings and 
increases the dimer binding energy by exclusion of water together with strengthening of 
native hydrogen bonding across the dimer interface. SOD1 dimer affinity is increased by 
both ebselen and ebsulphur binding irrespective of the SOD1 variant involved. As is the 
case for cisplatin and bis-maleimide derivatives, ebselen and ebsulphur are promiscuous 
thiol oxidases and form conjugates with a variety of proteins. However, the reaction with 
the target cysteine is reversible and likely to be stripped by cellular reductants such as 
glutathione. Indeed, our in-cell and in vitro NMR observations show that ebselen is not 
stably bonded to Cys111 in the reducing environment of the cytosol. Nevertheless, such 
reversible conjugation constitutes a novel means to modulate a behaviour of SOD1 
associated with ALS, and may become useful if the target is in less reducing 
environments at the point of intervention, such as the extracellular matrix or the 
mitochondrial inter-membrane space. Moreover, ebselen and ebsulphur are a more 
amenable scaffold from which to grow into the SOD1 dimer groove and engineer 
specificity than cisplatin or BMOE, whose mode of action is unclear or require covalent 
dimer tethering respectively. 
 
In recent years, the toxicity of large, insoluble SOD1 aggregates has been questioned. 
Monomers which are unable to bind zinc, fold and dimerize or small oligomers with non-
native interface regions are now thought to be the origin of SOD1 toxicity. In most cases 
these inherently unstable species are cleared by the cellular degradation machinery 
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leading to a reduction in the abundance and activity of mutant SOD1. Reduction in the 
amount of erythrocyte SOD1 is in fact strongly associated with ALS mutations (45–47). 
However, a fraction of mutant SOD1 does not undergo controlled degradation. Instead it 
sequesters and inhibits the proteasome and chaperone mediated folding pathways. 
Ultimately these species go on to form large insoluble aggregates but the damage has 
already been done and cell death ensues. While ebselen does not appear to form a stable 
covalent bond with SOD1 Cys111 in the reducing environment of the cytosol it does very 
efficiently redirect the fate of these small toxic species. We have shown, based on our in-
cell NMR characterization, that ebselen restores the mutant SOD1 post-translational 
modification pathway by promoting the formation of the intra-subunit disulphide bond. 
The mode of action of ebselen in cells has three possibilities: 1) An indirect effect on 
intracellular redox which promotes disulphide formation. 2) Increased activity of the 
SOD1 disulphide conferring chaperone protein hCCS. 3) Direct redox reaction between 
ebselen and SOD1 cysteines involved in the intra-subunit disulphide bond. While the first 
two hypotheses cannot be ruled out, we have shown the latter to occur spontaneously in 
vitro, in the absence of additional thiol-containing molecules. Therefore, ebselen likely 
reacts with one of the free Cys57 or Cys146 sulphydryls on SOD1, forming a transient 
selenyl-sulphide which is then easily rearranged by selenyl-thiol exchange to form the 
intra-subunit disulphide bond with the release of ebselen selenol. Disulphide bond 
formation greatly enhances the folding stability of mutant SOD1 and improves zinc 
binding affinity. Thus, the level of soluble mutant protein, which is constituted by SOD1 
not swiftly degraded or aggregated, is increased. In summary, by strongly promoting 
SOD1 disulphide formation, ebselen facilitates correct folding and zinc acquisition of 
mutant SOD1 in the cytosol, while in less reducing environments it greatly enhances the 
SOD1 dimer affinity (Fig. 6). Ebselen can therefore be considered a true pharmacological 
chaperone for SOD1. These positive effects are important milestones in SOD1-ALS drug 
development. 
 
To date, rational drug development for SOD1 has been impeded by insufficiently robust 
in vitro assays. This means drug screening has not effectively translated into clinical 
drugs. Two of the assay techniques used here, native mass-spectrometry and in-cell NMR, 
are novel in their application to SOD1 drug development. The insight we have gained 
through the combined use of multiple, highly complementary structural techniques has 
offered a new avenue for SOD1 drug discovery, promotion of disulphide formation, and 
new possibilities for analysis of drug molecules’ effect on characteristics pertinent to 
ALS. This has obvious benefits to the drug optimization process. 
 
The role of SOD1 in antioxidant defence cannot by understated. Indeed, nitroxidative 
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stress is elevated in ALS through the reaction of nitric oxide and superoxide to produce 
peroxynitrite. This can lead to tyrosine nitrosylation and glutamate excitotoxicity (48). 
Ebselen is known to inhibit inducible nitric oxide synthase, detoxify peroxynitrite and 
combat glutamate-induced excitotoxicity (49–51). This antioxidant behaviour, together 
with the pharmacological similarities with edaravone, indicate ebselen is likely to have 
positive secondary pharmacology as well as the primary pharmacological chaperone role 
investigated here. Several other drug-like molecules have shown negative on-target 
effects on the SOD1 interaction with hCCS (22). For SOD1 to perform its function it 
must be copper metalated and disulphide oxidized; a function largely performed by hCCS 
which takes E,Zn-SOD1
S-H
 as a substrate and yields active and highly stable SOD1. 
While cisplatin and BMOE inhibit or completely prevent the interaction with hCCS 
respectively, ebselen-bound SOD1 is free to heterodimerize with its protein chaperone in 
vitro despite the increased dimer affinity engendered by ebselen binding. If the 
reversibility and specificity of ebselen binding can be fine-tuned through rational, 
structurally-informed design, the implication is that SOD ’s toxic characteristics could be 
modulated in vivo over long time-courses for the treatment of ALS and asthma without 
damaging our response to oxidative stress. 
 
Materials & Methods 
Expression and purification of SOD1 
Recombinant wild-type and mutant SOD1 were expressed in BL21 (DE3) Escherichia 
coli as previously described (19). Apo-SOD1 variants were produced by dialysis against 
10 mM EDTA at pH 3.8 in sodium acetate buffer. Ebselen bound SOD1 was produced by 
adding the compound from a DMSO stock. Excess compound was removed by dialysis. 
H46R/H48Q SOD1 was analysed by SEC as described previously (22). Disulphide-
reduced E,Zn-SOD1 was obtained by adding 50 mM DTT to apo-SOD1 in phosphate-
buffered saline (PBS) and incubating for 40 min at 37°C. DTT was subsequently removed 
under anaerobic conditions and 1 equivalent of zinc was added. 
 
Crystallization and structure solution 
Crystals of as-isolated Zn bound SOD1 were produced using previously identified 
conditions with protein pre-conjugated with the ligand. Crystals were frozen in 3.2 M 
(NH4)2SO4 as a cryoprotectant and data were collected on I02 at Diamond Light Source 
and Proxima1 at SOLEIL for ebsulphur and ebselen bound SOD1 respectively. 
Diffraction images were indexed using iMosflm (52) and data was processed using the 
CCP4 suite (53). Models were manually refined using Coot (54) followed by cycles of 
restrained refinement in Refmac5 (55). Restraints for both ebselen and ebsulphur were 
produced using JLigand (56). Crystallographic statistics are shown in Table 1. The 
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structures of ebselen- and ebsulphur- bound SOD1 are deposited in the PDB with 
ascension numbers 5O40 and 5O3Y. 
 
Native mass spectrometry 
Native mass spectrometry analysis was performed using a SYNAPT G1 HDMS (Waters, 
UK) with parameters set according to previous work (31). Briefly, purified recombinant 
SOD1 protein was buffer exchanged into 200 mM NH4OAc (pH 6.8) using centrifugal 
concentrators with a 10 kDa molecular weight cut-off. Buffer exchanged SOD1 was 
diluted to working concentrations in NH4OAc, loaded into gold-coated borosilicate 
capillaries (made in-house), and subjected to nano-electrospray ionization (n=3 
electrosprays per dilution). All spectra were externally calibrated using 1 mg/mL 
caesium-iodide in 50% n-propanol, and were processed using Masslynx 4.1 software. 
Dissociation constants were determined according to Rose et al (57). 
 
Size-exclusion chromatography 
We used the artificial disulphide knock-out SOD1 mutant C57A/C146A to assay 
heterodimer formation with hCCS. This allowed us to bind ebselen to Cys111 only while 
maintaining the conditions necessary for complexation. 25 μM SOD1 was incubated with 
100 μM ebselen dissolved in 100 % DMSO for 3 hours at 20 oC. hCCS was desalted into 
nitrogen purged buffer. The complex was formed with 250 pmoles of both SOD1 and 
hCCS and was observed as described previously (22). Ebselen-free SOD1 was also 
treated with DMSO. 
 
Human cell culture and transfection 
HEK293T (ATCC CRL-3216) cells were maintained in DMEM high glucose (Life 
Technologies) supplemented with L-glutamine, antibiotics (penicillin and streptomycin) 
and 10% FBS (Gibco) in uncoated 75 cm
2
 plastic flasks, and were grown at 37°C, 5% 
CO2 in a humidified atmosphere. Cells were transiently transfected with SOD1 cDNA 
(either wild-type or mutant) cloned in the pHLsec plasmid(58) using polyethylenimine 
(PEI), as described previously
4
, with a DNA:PEI ratio of 1:1 (50 μg/flask DNA, 50 
μg/flask PEI). For wild-type SOD1, 25 μg/flask of cDNA was used (mixed with an equal 
amount of empty DNA vector) to compensate for the lower expression level of the 
mutants. [U-
15
N]-BioExpress6000 medium (Cambridge Isotope Laboratories) was used 
for in-cell NMR samples, supplemented with 2% FBS, antibiotics and 10 µM of ZnSO4. 
Ebselen treatment was performed by adding 200 µM ebselen to the external medium 24 h 
before collecting the cells. 200 µM was the highest concentration of ebselen which 
preserved cell viability and protein expression, chosen within a 10 µM – 1 mM range.  
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In-cell NMR sample preparation 
Samples for in-cell NMR were prepared following a reported protocol (59). Briefly, 
transfected cells were detached with trypsin, suspended in DMEM + 10% FBS, washed 
once with PBS and re-suspended in one pellet volume of DMEM supplemented with 90 
mM glucose, 70 mM HEPES and 20% D2O. The cell suspension was transferred in a 3 
mm Shigemi NMR tube, which was gently spun to sediment the cells. Cell viability 
before and after NMR experiments was assessed by trypan blue staining. After the NMR 
experiments, the cells were collected and the supernatant was checked for protein leakage 
by NMR.  
 
NMR experiments 
NMR spectra, both in-cell and in vitro, were collected at 308 K at a 950 MHz Bruker 
Avance III spectrometer, equipped with a CP TCI CryoProbe. For cell samples, 2D 
1
H-
15
N SOFAST HMQC (60) spectra (~1 h) were recorded with 64 scans, 2048 points, 128 
increments and a 0.3 s recycle delay. For in vitro NMR, samples of 130 µM E,Zn-SOD1 
in PBS, pH 7.4 were analyzed in 3 mm NMR tubes. 2D 
1
H-
15
N SOFAST HMQC spectra 
(~40 m) were recorded with 32 scans, 2048 points, 192 increments and a 0.3 s recycle 
delay. 
The NMR spectra collected were processed with Topspin NMR data-processing software. 
The in-cell NMR spectra were further processed by subtracting a spectrum of cells 
transfected with empty vector, acquired in the same experimental conditions, to eliminate 
the signals arising from partial 
15
N labelling of other cellular components. 
 
Western Blot analysis 
Cell lysates were prepared by freeze-thaw cycles in PBS buffer followed by 
centrifugation to remove the insoluble fraction. SOD1 (both wild-type and mutants) was 
stained with a rabbit polyclonal anti-superoxide dismutase 1 antibody (Abcam: ab16831, 
diluted 1:2000 to 0.5 mg/mL); a goat anti-rabbit IgG (whole molecule)-peroxidase 
secondary antibody (Sigma:A0545) was used, diluted at 1:80,000. SOD1 expression 
levels were normalized to GAPDH, which was stained with a rabbit polyclonal anti-
GAPDH antibody (Abcam: ab9485, diluted at 1:2000). LiteAblot EXTEND 
chemiluminescent substrate (EuroClone) was used for detection. 
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Figures & Tables 
 
 
 
Fig. 1: The structure of ebselen and ebsulphur bound to SOD1. (a) Cartoon 
representation of the SOD1 dimer with ebselen or ebsulphur molecules shown as 
ball and stick and bound to Cys111 residues at the dimer interface. (b) Omit map 
revealing the electron density of the missing ebselen compound before modelling. 
2Fo-Fc contoured at 1 σ in blue and Fo-Fc map contoured at   σ in green. (c and d) 
Electron density maps 2Fo-Fc contoured at 1 σ of (c) ebselen and (d) ebsulphur 
showing details of binding at Cys111 and proximal crystallographic waters. 
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Fig. 2: Conjugation of ebselen and ebsulphur to SOD1 variants increases the 
binding affinity of the dimer. (a) SOD1 variants (wild-type, A4V, H46R/H48Q, 
G93A, and I149T) with ebselen (red), ebsulphur (blue), and without treatment 
(black) were buffer exchanged into 200 mM NH4OAc and subject to nanoESI mass 
spectrometry at different protein concentrations under gentle conditions optimised to 
maintain non-covalent interactions. Curves show the percentage of monomer signal 
as a function of protein concentration with determined dimer KD values inset for 
each SOD1 variant. (b) The fold-increase in binding affinity of each SOD1 variant 
when ebselen or ebsulphur is conjugated at Cys111. 
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Fig. 3: Ebselen does not prevent heterodimer formation with hCCS. Size 
exclusion chromatograms showing how ebselen binding to C57/146A SOD1 
promotes dimerization (blue dashed line to red dashed line) but does not inhibit 
complex formation with wild-type hCCS. 
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Fig. 4: Ebselen efficiently oxidizes SOD1 in living cells. (a) Overlay of 
1
H-
15
N 
NMR spectra acquired on human cells expressing [U-
15
N] labelled wild-type E,Zn-
SOD1 in absence (red) and in presence (black) of ebselen in the external medium. 
(b) Overlay of 
1
H-
15
N NMR spectra acquired on purified, disulphide-reduced [U-
15
N] labelled wild-type E,Zn-SOD1 before (blue) and after (magenta) treatment with 
1 equivalent of ebselen. Signals affected by the formation of the C57-C146 
disulphide bond are labelled (bottom panels). 
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Fig. 5: Ebselen stabilizes ALS mutant SOD1 in living cells. (a) Overlay of 
1
H-
15
N 
NMR spectra acquired on human cells expressing [U-
15
N] labelled SOD1 ALS 
mutants G93A (a) and A4V (b) in absence (green/orange) and in presence (black) of 
ebselen in the external medium. NMR signals clustered in the region around 8.3 
p.p.m. (
1
H) are characteristic of unstructured SOD1 species. (c) Western Blot 
analysis of cell lysates expressing wild-type and mutant SOD1 in absence and in the 
presence of ebselen. (d) expression levels of wild-type and mutant SOD1 in cell 
samples treated with ebselen relative to the corresponding untreated samples; error 
bars represent s.d. (n = 3); * indicates significant differences (ratio t-test, p < 0.05). 
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Fig. 6: Mechanism of SOD1 stabilization by ebselen. In the absence of ebselen 
monomeric, disulphide reduced, metal-free mutant SOD1 is highly likely to remain 
globally unfolded and be degraded or accumulate as small toxic oligomers or 
aggregates which are characteristic of ALS neural tissues (red). However, in reaction 
1 ebselen forms a selenylsulphide bond with either Cys57 or Cys146 on newly 
translated SOD1. 2. Selenol-disulphide exchange forms the SOD1 intra-subunit 
disulphide bond and frees the ebselen selenol. Reduction of hydrogen peroxide by 
ebselen selenol reforms the ebselen heterocycle. This recycling process indicates 
that relatively small amounts of ebselen could promote SOD1 maturation. 3. SOD1 
disulphide formation promotes correct folding, zinc binding and dimerization. 4. 
Further modification of Cys111 by ebselen prevents monomerization by ALS 
mutations thus maintaining stable, active, fully metalated, homodimeric SOD1. 
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Table 1: Crystallographic statistics for SOD1 bound ebselen and ebsulphur 
structures. 
 
 wtSOD1-ebselen wtSOD1-ebsulphur 
Data collection   
Space group P 21 P 21 
   
   a, b, c (Å) 38.10  67.84  51.04 38.05  67.96  51.18 
   , ,  ()  90.00  106.35  90.00 90.00  106.73  90.00 
Resolution (Å) 49.01 – 1.50 (1.52-1.50) * 67.84 – 1.30 (1.33-1.30) * 
Rmerge 11.7 (59.4) 6.4 (56.6) 
I / I 5.9 (1.5) 7.1 (1.4) 
Completeness (%) 99.9 (99.5) 98.8 (97.7) 
Redundancy 3.1 (3.1) 3 (2.8) 
   
Refinement   
No. reflections 39891 60537 
Rwork / Rfree 16.05 / 21.24 14.53 / 18.10 
No. atoms   
    Protein 2241 2274 
    Ligand/ion 46 46 
    Water 309 311 
B-factors   
    Protein 12.35 15.45 
    Ligand/ion 10.32 15.47 
    Water 29.27 35.38 
R.M.S. deviations   
    Bond lengths (Å) 0.013 0.015 
    Bond angles () 1.607 1.683 
*Values in parentheses are for highest-resolution shell. 
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2.3. Sample preparation: towards protein interacting systems 
by in-cell NMR 
2.3.1. Solution in-cell NMR meets solid state NMR 
Despite the fact that in-cell NMR is a powerful technique to study protein 
structures and dynamic inside cells, the nature of the investigated protein and the 
complexity of the intracellular environment can considerably impact on the 
possibility of detecting the NMR signals for the protein of interest. In fact, the 
protein experiences interactions of various nature that might affect its relaxation 
properties: from specific direct interaction with physiological partners to weak 
and non-specific ones with molecular assemblies or cellular components (nucleic 
acids, cellular membranes, protein complexes) that slow down the average 
molecular tumbling rate and increase relaxation rates and signal broadening [60, 
61, 62, 63]. 
We hypothesized that soluble proteins that experience intermolecular 
interactions so strong that their lines are broadened beyond detection in solution 
could, at least in part, behave as a solid within the cells. For these systems, solid 
state NMR could be a suitable technique to overcome the limitations of solution 
in-cell NMR.  
When the molecular tumbling is abolished, one can imagine that the protein 
will be observed as it was “frozen” in a set of orientations with respect to the 
magnetic field. In this regime, each molecule senses a different value for all the 
nuclear spin interactions, which are anisotropic in nature, instead of rapidly 
interconverting among different values. In a static sample, therefore, each nuclear 
signal intensity would be spread over a frequency range larger than a single line. 
To average out these effects, Magic Angle Spinning (MAS) condition is applied to 
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the sample. In the MAS condition the sample is tilted by a specific angle (54.74°) 
respect to the external magnetic field direction that averages out the dipolar 
interaction, and it undergoes a fast spinning to mimic molecular tumbling in 
solution. In the last years, MAS ssNMR was successfully used to investigate 
molecules inside native membranes or to characterize proteins involved in high 
molecular-weight complexes within the cytoplasm. [64, 65]. In these examples, 
the protein of interest was either extracted by isolating the native membranes, or 
the whole cell preparation was analyzed at sub-freezing temperatures. Here, we 
investigated the possibility of applying room-temperature MAS ssNMR to 
investigate proteins which are invisible in the cell, due to their interactions with 
cellular components. 
2.3.1.1. Protein models 
Cytochrome c (Cyt c) is a conserved globular hemeprotein of 104 amino acid 
residues in mammals that shows multiple functions in the cell: it is essential in 
electron transfer in the mitochondrial respiratory chain in the IMS, and has a 
pivotal role in triggering cell apoptotic pathways [66]. In the IMS, Cyt c also 
exerts a peroxidase cardiolipin activity [67], it is involved in the mitochondrial 
oxidative protein folding machinery [68], and functions as radical scavenger [69]. 
It has been selected as a case study for cellular solid state NMR trials because it is 
one of those soluble proteins that are not detectable by solution in-cell NMR and 
it might has a solid-like behavior since it has been reported to interact and to bind 
the anionic phospholipid cardiolipin [66]. Indeed, it was previously shown that 
Cyt c expressed in bacteria cannot be detected by solution NMR, also upon cell 
lysis, due to strong interactions of its surface lysine residues with the bacterial 
membrane, or with negatively charged macromolecules [70]. 
Human Profilin 1 (PFN1) is a ubiquitously expressed 139-residues globular 
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protein involved in a complex network of molecular interactions [71]. Recently 
mutations on the PFN1 gene have been linked to familial ALS. Three single-
amino acid mutants have been found to be pathogenic for fALS inducing PFN1 
aggregation, C71G, M114T and G118V, and a fourth mutant, E117G, has been 
proposed to be a risk factor for developing ALS [73]. To date, little is known 
about the mechanisms through which PFN1 is involved in ALS pathogenesis. It 
has been shown that PFN1 pathological mutants display aggregation propensities, 
display functional differences compared with the wild-type protein, such as a 
lower bound actin level, inhibition of axonal outgrowth and dynamics [REF71]. The 
effect of these mutations on PFN1 protein stability and structure revealed that 
mutants create a cleft that extend into the interior of PFN1 destabilizing the native 
protein’s conformation [74]. Among the reported profilin 1 mutants, M114T was 
selected as a case study for cellular solid state NMR trials, as it was found to form 
insoluble aggregates, which are expected to have a solid-like behavior, when 
overexpressed in bacteria. 
The human Menkes 6 (MNK6) protein is the sixth soluble domain of the 
ATP7A protein presented in (Protein model system 2.5.2.1). It is also not 
detectable by solution in-cell NMR, and therefore it was selected as it benefits 
from in cell SSNMR characterization. 
2.3.1.2. Results 
We first assessed whether intracellular soluble proteins could be sedimented under 
MAS conditions at room temperature. To this aim, we focused on the soluble 
protein SOD1, which was already characterized by solution in-cell NMR, 
expressed in bacteria. SOD1 was overexpressed in E. coli grown in [
15
N, 
13
C] 
enriched minimal medium M9 (Methods 4.2.1.1). The signals observed in the 
monodimentional experiments (
1
H-
13
C INEPT) indicated that a fraction of the 
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labelled molecules of the cell is mobile. Simultaneously, the 
13
C-
13
C DARR [75] 
spectrum, Fig. 2, contained signals likely arising from an immobilized protein 
fraction inside the cells. Unfortunately, the low labeling specificity and the low 
resolution of the signals did not allow us to identify unambiguously signals 
belonging to SOD1. Therefore, further tests were focused on more suitable 
proteins, which were expected to behave as solids within the cells, either due to 
strong interactions with other cellular components or to the propensity to form 
insoluble aggregates. 
 
Figure 2. 2D 13C-13C DARR in-cell solid state NMR spectra: E. coli cells expressing SOD1 (black) 
superimposed to a reference NMR spectrum of SOD1 in vitro (red). The spectra are recorded at 700 MHz, 14 
kHz, τ mix=  0 ms, rotor  .2 mm, T=276 K (effective sample temperature). 
The first candidate protein not detectable by solution in-cell NMR 
investigated was human cytochrome c (Cyt c). The protein was overexpressed in 
E. coli grown in [
15
N 
13
C] enriched minimal medium M9 (H2O) (Methods 
4.2.1.2). The 
13
C-
13
C DARR spectrum of Cyt c in E.coli, shown in Fig 3, 
presented unresolved peaks. This might be due to the sample low labeling 
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selectivity: in fact, the cytochrome c expression protocol requires three days of 
protein expression in [
15
N 
13
C] enriched media. In order to assess the contribution 
of Cyt c to the spectra, we repeated the same NMR experiments on a ‘blank’ E. 
coli sample not overexpressing any protein, prepared with the same expression 
protocol (Methods 4.2.1.2). Ideally, subtraction of the ‘blank’ spectrum would 
allow to better discriminate which peaks belong to the protein of interest. Despite 
the low spectral resolution and the presence of artifacts did not allow a proper 
subtraction, qualitative comparison of the two 
13
C-
13
C DARR spectra suggests 
that no resolved signals of Cyt c are present in the first spectrum (Figure 3). 
Overall, these spectra show that the non-specific labeling of all cellular 
components greatly limits the ability to obtain well-resolved signals of the protein 
of interest. 
In an attempt to improve both the resolution and the selectivity of the NMR 
experiment towards the signals of interest, we exploited heteronuclear correlation 
experiments, namely NCA double cross-polarization [76]. In parallel, partial 
Figure 3. 2D 13C-13C DARR in-cell solid state NMR in black the spectrum of E. coli expressing 
cytochrome c. In red the superimposition of a ‘blank’: in cell spectrum of E. coli not expressing 
cytochrome c. The spectra are recorded at 700 MHz,    kHz, τ mix=  0 ms, rotor 4 mm, T=284 K 
(effective sample temperature). 
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deuteration of the expressed protein was tested. To this aim, we set up a protein 
overexpression protocol in minimal medium containing  98% D2O (Methods 
4.2.1.3) without previous adaptation. In this protocol [
1
H,
13
C] glucose was used as 
carbon source, resulting in side chain deuteration mostly at the α and partially at 
the β position [77]. With this labeling protocol, partially deuterated, [13C,15N]-
labeled insoluble mutant of PFN1, M114T, was expressed. 
The NCA spectra recorded, shown in Fig 4, present low resolution in the 
nitrogen dimension. Nevertheless, there are some resolved peaks in the C region, 
and some glycine signals can be distinguished (~ 43 ppm 
13
C). 
 
Figure 4. 2D 15N-13C NCA in-cell solid state NMR spectrum Profilin mutant M114T overexpressed in E. 
coli grown in 98% D2O. The spectra are recorded at 850 MHz, 14 kHz, 3.2 mm, NCA contact time=3 ms, 
T=303K (effective sample temperature). 
Such low resolution might still be due to the cellular background arising from 
non-specific labeling or, more likely, to the fact that the protein forms amorphous 
aggregates where multiple protein conformations spread the resonances in the 
ssNMR spectra. 
51 
Finally, we assessed whether chemical cross-linking could stabilize the 
immobilized conformation of the cellular components, producing a more solid-
like cell sample, despite sacrificing cell viability. To this aim, we incubated 
bacterial cells overexpressing MNK6 with Paraformaldehyde (PFA) (Methods 
4.2.1.4). In addition, CP-NOE pulse sequences were applied to better monitor the 
changes in intensity of the mobile part of the sample [78]. In the spectra shown in 
A Fig. 5, we observed a general signal decrease suggesting that PFA fixation 
decreased the amount of mobile cellular components to some extent. Despite this, 
the 
13
C-
13
C DARR ssNMR on the fixed cells sample presented in B Fig. 5, 
showed signals with low intensity and low resolution. Alternative cellular fixation 
procedures with different percentage of PFA and/or diverse fixative compounds 
might be investigated in order to further decrease the internal protein mobility. 
 
Figure 5. Solid state NMR of E. coli overexpressing MNK6 in A) comparison between PFA treated and 
untreated cells with 1H-13C CP-NOE recorded at 700 MHz, 14 kHz, τ mix= 2.2 s, rotor 3.2 mm, T = 284 K 
(effective sample temperature) in B) 2D 13C-13C DARR in-cell solid state NMR recorded at 700 MHz, 14 
kHz, τ mix= 2.2 s, rotor 3.2 mm, T = 284 K (effective sample temperature). 
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2.3.2. Merging DNA transfection and protein delivery electroporation 
The approach for in-cell NMR in human cells recently developed in our 
laboratory relies on transient transfection and protein overexpression of human 
HEK293T cells, and allows stable isotope labeling of one or more proteins of 
interest. Using this protocol, metal and chaperone dependent maturation processes 
were successfully characterized for several proteins involved in copper 
homeostasis and redox regulation [13, 14]. In order to expand the strategies for 
sample production, the aim of this activity within my PhD project was to combine 
protein transfection with protein delivery techniques to characterize intracellular 
protein-protein interactions at atomic resolution. For such purpose, the ability to 
actively deliver isotope-labeled recombinant proteins by electroporation opens up 
many possibilities, such as greatly reducing the cellular background resulting 
from non-specific isotope incorporation, therefore gaining selectivity. Moreover, 
electroporation would allow the production of in-cell protein samples with various 
labeling strategies (e.g. selective modification of individual protein residues, 
fluorescent or paramagnetic tagging). 
2.3.2.1. Protein model system 
Copper is an essential trace metal central to eukaryotes life [79]. While it operates 
as cofactor for a wide range of catalytic functions, it can be potentially toxic for 
cells if its redox reactivity is not strictly controlled. Therefore, copper trafficking 
and homeostasis always occur throughout tightly regulated pathways involving 
copper transporting proteins [80]. Among the known copper-binding proteins, we 
focused on ATP7A, a major regulator of copper homeostasis in human cells. 
ATP7A, also called Menkes protein (MNK), is a P-type transmembrane ATPase 
involved in the maturation of secreted copper proteins. It is responsible for 
transferring copper from the cytosol to the Golgi lumen by receiving Cu(I) from 
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the cytosolic chaperone HAH1. ATP7A is also involved in the export of excess 
copper through fusion of ATP7A-enriched vesicles with the plasma membrane. 
Mutations in ATP7A lead to a dysfunction in copper transport across membranes 
that results in a fatal X-linked copper deficiency syndrome, the Menkes disease 
[81, 82]. ATP7A is constituted of four major regions: the transmembrane domain, 
the ATP-binding domain, the phosphatase domain and the cytosolic copper 
binding domain. The N-terminal copper-binding cytosolic region contains six 
folded domains, which share similar sequence, structure and a conserved Cu(I) 
binding motif (GMXCXXC) [83, 84]. The mechanism through which the 
metallochaperone HAH1 delivers Cu(I) to MNK cytosolic domains has been 
extensively detailed by in vitro, also by solution NMR [85, 86]. To achieve our 
purpose of expanding the sample preparation methods for in-cell NMR, we 
selected as a case study the metal-mediated transient complex formed between the 
first cytosolic domain of ATP7A (MNK1) and the copper chaperone HAH1.  
2.3.2.2. Results 
The first experimental step was the check of MNK1 suitability to be 
overexpressed in HEK293T cells and to be detectable by in-cell NMR 
experiments. As Fig. 6 shows in A, unfortunately HEK293T cells transiently 
transfected with a synthetic gene encoding MNK1 presented almost no signals 
belonging to a folded protein. Despite MNK1 being present in the sample, as 
confirmed by SDS-PAGE analysis, no signals related to MNK1 were detected as 
well in the spectrum of the cell lysate. This result might be related to non specific 
interactions occurring between MNK1 and other cellular components, that are still 
preserved when the cells are broken and the NMR experiments are run on the 
lysate. 
We also performed in-cell NMR experiments on HAH1-transfected 
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HEK293T cells and, as it is reported in Fig. 6 B, we obtained a high-quality 
spectrum showing well resolved peaks where the signals arising from the HAH1 
folded protein are clearly identified. 
 
Figure 6. 2D 1H-15N SOFAST-HMQC in-cell NMR spectra of HEK293T cells in A) overexpressing wild 
type MNK1 protein; in B) overexpressing wild type HAH1 protein. 
In light of these results, we changed our strategy and we aimed to express 
HAH1 in cells and subsequently incorporate, through electroporation, Cu(I)-
loaded MNK1.  
We performed in vitro NMR tests to verify that protein-protein interactions 
and complex formation occur upon titration of Cu-MNK1 with apo-HAH1, as this 
would be the reverse of what is known to occur in vivo, where HAH1 is the 
physiological metallo-chaperone that transfers copper to MNK1.  
We followed the complex formation between 
15
N Cu(I) MNK1 and apo-
HAH1 via NMR titration starting with a Cu(I)MNK1 concentration of 70 µM. As 
shown in Fig. 7, some of the signals corresponding to residues in the proximity of 
the binding interface between MNK1 and HAH1 protein are shifted or broadened 
(E15, T25, Q28, G70), while other signals closer to the binding site disappear 
(T18, S21, C22). 
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Figure 7. 2D 1H-15N SOFAST-HMQC in vitro NMR spectra comparison superimposition  the spectrum of 
Cu(I)MNK1 protein, in black, and the complex Cu(I)MNK1-HAH1 formed, in purple.  
In order to determine the percentage of MNK1 involved in the complex with 
HAH1, we performed 
15
N NMR relaxation experiments to calculate the average 
molecular tumbling rate (τ) in a sample of MNK1:HAH1 in 1:1 molar ratio and 
for a protein concentration of 75µM each, in conditions comparable to the 
previous in vitro titrations. The data analysis of the 
15
N relaxation rates reveals 
that ~50% of the 15N-Cu(I)MNK1 protein is complexed with HAH1. 
We also tested the stability of the formed complex when it is inside a cellular 
lysate. From the NMR data, as is shown in Fig. 8, we can see that the spectrum 
maintain the characteristics of the complex formed and the peaks related to the 
Cu(I)MNK1 protein alone do not appear. 
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Figure 8. 1H-15N SOFAST-HMQC spectra comparison: in black the spectrum of Cu(I)MNK1-HAH1 
complex in vitro 70 µM , in purple Cu(I)MNK1-HAH1 70 µM complex inside a HEK293T cellular lysate. 
Having been able to detect by NMR the complex and its stability over the 
NMR experimental time in a cellular lysate, we were encouraged to start working 
on setting up the procedures for protein delivery. A series of ‘small scale’ 
electroporation trials in HEK293T cells were performed using purified 
Cu(I)MNK1 as protein to be delivered. The electroporation set up was followed 
according to [11]. Different electroporation conditions were tested and the protein 
insertion efficiency was followed and analyzed via Western Blot. The conditions 
that allowed higher levels of delivered protein were selected (METHODS 4.7.1).  
Immunocytochemistry (ICC) analysis was performed in order to determine 
the delivered protein localization, after setting the best condition for cell 
adherence and fixation. Several florescence microscopy tests on the primary 
antibody against MNK1 revealed that it is not suitable for Fluorescence analysis 
because of a nonspecific cytosolic binding behavior of the primary antibody. 
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Viability tests had shown a 25-30% survival after the electroporation procedure in 
HEK293T cells. 
A HEK293T-derived cell line stably overexpressing HAH1, previously 
obtained in our laboratory [87], was selected as an additional cellular system to 
perform delivery trials. From the characterization pursued by Western Blot and 
ICC analysis on this stable cell line, HAH1 protein expression levels and HAH1 
localization were obtained (Methods 4.7.3). From the ICC data comparison 
between HEK293T cells transiently transfected with HAH1 and those stably 
expressing HAH1, the presence of HAH1 in the cytoplasm appears to be much 
more uniform in expression level and in distribution inside the stable cell line 
(METHODS 4.5). Therefore, the stable cell line for HAH1 was chosen as first 
operative system for MNK1 electroporation trials. 
Before producing a ‘full scale’ in-cell NMR sample, in the first place we 
tested the MNK1 protein behavior at very low concentration in a cellular extract, 
mimicking at best the real cellular contest either for HEK293T cells or for the 
stable cell line for HAH1. Firstly, we tested some lysis conditions; the best ones 
resulted to be: a wash in PBS and 6 cycles of freeze and thaw. The total protein 
concentration of all the crude cell extracts was then determined by the Bradford 
assay. For the in-lysate NMR experiments, lysate of both HEK293T cells and of 
stable cell line for HAH1 were used. The total protein concentration was 
measured as 24mg/ml, pH 7.2. The Cu(I)MNK1 final concentration was 10 µM. 
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Figure 9. 1H-15N SOFAST-HMQC in lysate NMR spectra A) in red, 10 µM Cu(I)MNK1 in HEK293T cell 
crude extract B) in light blue, 10 µM Cu(I)MNK1 in stable HAH1 cell line crude extract; in both cases, 
superimposed on the in vitro reference spectrum of 20 µM Cu(I)MNK1, in black. The spectra are recorded at 
pH 7.2 T=293.8 K. 
From the spectra reported in Fig. 9, it appears that the majority of the MNK1 
signals are present also in a close-to-cellular context. The disappearance of a few 
signals might be due to some interactions with cellular components. The two 
spectra differ for the presence (B) or absence (A) of the partner protein HAH1. 
Interestingly, the pattern of signals disappearance presents some differences 
between the two spectra A and B. Only the spectrum of cells containing also the 
partner HAH1 presents signals shifts and signal disappearances that are diagnostic 
of the complex formation, such as C22, G70, M69 as presented in Fig. 10: 
 
 
 
 
Figure 10. Superimposition of 2D 1H-
15N SOFAST-HMQC in lysate NMR 
spectra: spectrum of 10 µM Cu(I)MNK1 
in HEK293T cell crude extract in red, 
compared to 10 µM Cu(I)MNK1 in 
stable HAH1 cell line crude extract, in 
light blue. 
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This might suggest that the complex formation is possibly taking place 
together with interactions with unknown cellular components. Prompted by these 
encouraging results, we went on setting up the 'full scale' in-cell NMR sample. In 
Fig. 11, the spectra showing both HEK293T and stable cells expressing HAH1 
electroporated with 
15
N Cu(I)MNK1 are reported 
 
Figure 11. 2D 1H-15N SOFAST-HMQC in-cell NMR: in A) in red, delivered Cu(I)MNK1 in HEK293T cells 
B) in light blue, Cu(I)MNK1 in stable HAH1 cell line; in both cases, superimposed on the in vitro reference 
spectrum of 20 µM Cu(I)MNK1, in black. Spectra are recorded at pH 7.2 T=293.8K. 
 
Almost no signals were detected in the spectra of either HEK293T cells or of 
the stable cell line for HAH1, except two broad peaks in the glutamine region that 
could arise from the 
15
N natural abundance asparagine/glutamine in the medium. 
Some broad signals are observed, clustered in the region of the amide protons 
(around 8.3 ppm). The position and the shape of the peaks might be attributable to 
MNK1 in an unfolded state. Alternatively, they could arise from the 
15
N natural 
abundance of the cellular background. Western blot analysis confirmed the 
presence of MNK1 inside the cell samples, in particular in the soluble fraction 
(Methods 4.7.2). Based on these results, we might speculate that the 
electroporation procedure itself caused an unfolding of MNK1. Such effect, likely 
protein-dependent, would impose some limitations to the electroporation 
approach, and needs to be investigated further. 
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3. CONCLUSIONS AND PERSPECTIVES 
In this doctorate project, the in-cell NMR approach was applied to detail proteins 
redox state inside different cellular environments. The oxidation state and the 
folding of disulfide-containing proteins (human Cox17, Mia40 and SOD1) were 
investigated inside human and bacterial cells. Our findings showed that the 
glutathione redox potential of the cytoplasm cellular compartment alone does not 
determine the redox state of a given protein. Indeed, in human cells, co-expression 
of redox-regulating protein partners altered the distribution of redox states, 
whereas in bacterial cells, despite the less reducing environment, the absence of 
the disulfide reduction pathways (in Origami B cells) caused the predominance of 
the oxidized state of each protein. From the methodological point of view, in-cell 
NMR proved to be a suitable method for the non invasive direct observation of 
protein redox states inside living cells.  
Furthermore, in-cell NMR was successfully applied to characterize the 
interaction of the small antioxidant molecule ebselen with disease-related SOD1 
mutants inside human cells. The data obtained complemented the in vitro 
observations, and showed that ebselen facilitates the correct folding of 
destabilized SOD1 mutants by promoting the proper maturation pathway, 
inducing the disulfide bond formation and the zinc binding. Ebselen might 
therefore be considered a true pharmacological chaperone for SOD1. These 
positive effects represent a promising starting point for future SOD1-ALS drug 
development. 
In this doctorate project, an effort to increase the applicability of in-cell NMR 
was undertaken in two main directions, focusing on new sample preparation 
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approaches.  
A first direction aimed at enabling in-cell NMR investigations of those 
soluble proteins that experience interactions within the cells that negatively 
impact their relaxation properties, broadening signals beyond detection. To this 
aim, solid state NMR was chosen as a technique to overcome the limitations of 
solution in-cell NMR. The results deriving from the investigation on various 
proteins, diverse sample preparation and different NMR experiments highlighted 
several issues linked to the experimental setup, which need to be further addressed 
for future development. Most critical is the need of an efficient and selective 
protein labeling strategy, in order to distinguish the signals belonging to the 
protein of interest from the background arising from other cellular components. 
Further, our data showed that many proteins, undetectable by solution NMR, 
could not be detected also when investigated through MAS solid state NMR, as if 
they were not behaving as a “true solid”. Such need for a more solid-like sample 
could possibly be addressed by pursuing alternative chemical cross-linking 
approaches, in order to immobilize the conformation of the cellular components 
and of the protein of interest. Such approach would sacrifice cell viability (and 
lose the status of ‘NMR in living cells’) in favor of improved sample preservation 
and longer experimental times.  
The second direction aimed at enabling the characterization by solution in-
cell NMR of intracellular protein-protein interactions, through a combination of 
protein transfection techniques with a versatile protein delivery strategy, 
electroporation. From the data obtained, the electroporation procedure itself seems 
to have a negative effect on the protein folding state. The observed protein 
unfolding, which might be driven by local changes in electrostatic potential or 
temperature, prevented additional studies on the investigated protein system. 
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Further developments should focus on this adverse effect of the electroporation 
procedure, in order to understand its protein-dependence and to devise milder 
electroporation conditions. 
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4. METHODS 
 
4.1. Recombinant protein production 
4.1.1. Human ATP7A domain 1 (MNK1) 
A culture of BL21 DE3 Rosetta pLysS transformed with the pET21 plasmid 
encoding his-tagged MNK1 was grown in M9 medium containing 
[
15
N]ammonium sulfate at 37°C, 180 rpm. Cells were induced at OD600= 0.6 with 
0.5 mM Isopropil-β-D-1-tiogalattopiranoside (IPTG). Protein expression was 
carried on over night at 20 °C. The cells were harvested and centrifuged 20 
minutes at 4500 rpm. Cell lysis was performed in 20 mM Na2HPO4 buffer, 0.5 M 
NaCl, 5 mM imidazole, pH 8 through sonication. The lysate was centrifuged at 
40000 rpm for 30 minutes, and the soluble fraction was separated from the pellet. 
The soluble fraction was loaded on a HisTrap affinity Ni-column equilibrated with 
binding buffer: 20mM Na2HPO4, 0.5 M NaCl, 20 mM imidazole, pH 8, and 
washed with 20 mM Na2HPO4, 1 M NH4Cl, 20 mM imidazole, pH 8. The 
protein was eluted in 20mM Na2HPO4 buffer, 0.5 M NaCl, 5 mM imidazole, 20 
mM EDTA, pH 8. Cleavage of Histag was obtained by incubating overnight with 
Factor Xa. Cu(I) binding was performed anaerobically inside a glovebox (Coy 
Laboratory) filled with N2, to preserve the copper oxidation state. Copper(I) was 
added to samples adding an acetonitrile solution of tetrakis(acetonitrile)copper(I) 
hexafluorophosphate ([(CH3CN)4 Cu]PF6 ) in the presence of 1 mM dithiothreitol. 
64 
4.1.2. Human HAH1 
A culture of BL21 DE3 Gold transformed with the pET15 plasmid encoding his-
tagged HAH1 was grown in M9 medium containing (either unlabeled or [
15
N]) 
ammonium sulfate at 37°C, 180 rpm. Cells were induced at OD600= 0.6 with 
0.5mM IPTG. Protein expression was carried on for 5 hours at 37 °C. The cells 
were harvested and centrifuged 20 minutes at 4500 rpm. Cell lysis was performed 
in 20mM Na2HPO4 buffer, 0.5 M NaCl, 5 mM imidazole, pH 8 through 
sonication. The lysate was centrifuged at 40000 rpm for 30 minutes, and the 
soluble fraction was separated from the pellet. The soluble fraction was loaded on 
a HisTrap affinity Ni-column equilibrated with binding buffer: 20mM Na2HPO4, 
0.5 M NaCl, 20 mM imidazole, pH 8, and washed with 20 mM Na2HPO4, 1 M 
NH4Cl, 20 mM imidazole, pH 8. The protein was eluted in 20mM Na2HPO4 
buffer, 0.5 M NaCl, 5 mM imidazole, 20 mM EDTA, pH 8. A Size-exclusion 
column chromatography Superdex75 16/60 in buffer Tris Buffer 20 mM, NaCl 
100 mM was run. 
4.2. In cell solid-state NMR sample preparation 
4.2.1. Bacterial cells 
4.2.1.1. SOD1 
A culture of 250 mL of E.coli BL21 gold expressing wild type SOD1 in pET28 
was grown in M9 medium containing [
13
C]glucose and [
15
N]ammonium sulfate. 
Induction was performed with 0.5 IPTG, Protein expression was carried on for 4 
hours at 30°C, 180 rpm. Cell were harvested and washed twice with M9. The cell 
pellet was used to fill a 3.2 mm rotor to perform solid-state NMR experiments. 
The viability of the sample before and after the NMR experiments was tested via 
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plating test, none gave positive results.  
4.2.1.2. Cytochrome c 
A culture of 250 mL of E.coli BL21(DE3)C41 expressing human cytochrome c in 
pET21 plasmid was grown in M9 medium containing [
13
C]glucose and 
[
15
N]ammonium sulfate. The culture was grown at 30°C at 60 rpm up to OD > 1, 
then protein expression was induced with 0.5 mM IPTG. The cofactors Sodium 2-
mercaptoethanesulfonate (MESNA) and delta-aminolevulinic acid (∂-ALA) were 
added together with FeSO4 at the time of induction. Protein expression was then 
carried on for 3 days at 30°C and 60 rpm. Cell were harvested and washed twice 
with M9. The pellet was used to fill a 4 mm rotor to perform solid-state NMR 
experiments. The viability of the sample after the NMR experiments was tested 
via plating test but none gave positive results. 
4.2.1.3. Profilin mutant M114T 
The aggregation-prone profilin mutant M114T was chosen as a candidate protein 
to set up a deuteration protocol. Several expression tests changing growing 
volumes (2 mL, 4mL, 50mL) and growth temperature (25°C and 37°C) were 
performed on E.coli BL21 gold. Expression tests revealed by SDS-PAGE that the 
protein is mainly in the insoluble fraction and that 37°C is the eligible temperature 
for the higher protein overexpression, shown in Fig. 12. 
 
Figure 12. SDS-PAGE on 
gradient precast gel 4-20% 
Profilin mutant M114T. a) 
unstained protein marker; 
b)soluble fraction and c) 
insoluble fraction of , E.coli 
expressing M114T at 25°C; d) 
soluble fraction and e) insoluble 
fraction of E.coli expressing 
M114T at 37°C. 
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Freshly transformed colony were grown in minimal medium containing98% 
D2O in aerated shaker at 37°C and 275 rpm. The precoltures reaching O.D.600=0.8 
were selected. Cells were spun down at 2900g for 20 minutes at 4°C, washed once 
with fresh D2O M9 1x and resuspended in D2O M9 1x supplemented with 
antibiotics and vitamins. Induction with 0.5 mM IPTG was followed by 4 hours 
expression. Cell were harvested and washed once with M9. The pellet was used to 
fill the 3.2 mm rotor to perform solid-state NMR experiments. The viability of the 
sample after the NMR experiments was tested via plating test but none gave 
positive results. 
4.2.1.4. MNK6 
A culture of 250 mL of E.coli BL21 Rosetta pLysS expressing ATP7A sixth 
soluble domain (MNK6) in the pET21 was grown in M9 medium containing 
[
13
C]glucose and [
15
N]ammonium sulfate. Induction took place with 0.5 IPTG, 
protein expression was carried on for 4 hours at 30°C 180 rpm. Cell were 
harvested and washed twice with M9. The cell sample was splitted in two equal 
amounts, one was used to fill up the 3.2 mm rotor to perform monodimentional 
solid-state NMR experiments, while the other one was treated with 4% 
Paraformaldehyde (PFA) for 20 minutes and used to fill up the 3.2 mm rotor to 
perform solid-state NMR experiments. The viability of the sample after the NMR 
experiments was tested via plating test but none gave positive results. 
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Figure 13: 4-20% gradient SDS-PAGE protein expression check on bacterial samples for solid state 
NMR experiments: A) in a the unstained protein marker, in b E.coli BL21 gold expressing SOD1; B) in a the 
unstained protein marker, in c E.coli BL21 C41 grown following cytochrome c expression protocol but 
without induction, in d E.coli BL21C41 expressing cytochrome c; C) in a the unstained protein marker, in e 
E.coli BL21 gold grown in ~100% D2O expressing M114T Profilin mutant, in f E.coli BL21 gold grown in 
~100% D2O without induction, D) in a the unstained protein marker, in g of E.coli BL21 Rosetta pLysS 
grown following MNK6 expression protocol but without induction, in h E.coli BL21 Rosetta pLysS 
expressing MNK6.  
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4.3. Protein delivery sample preparation: electroporation 
HEK293T cells at low passage number were prepared by seeding 2×10
6
cells/flask, 
culturing the cells for two days in complete medium, low-glucose Dulbecco’s 
modified Eagle medium (DMEM, Gibco), supplemented with 10% fetal bovine 
serum (FBS, Gibco) until 80% confluence was reached. Cells were harvested by 
being exposed to 0.25% trypsin/EDTA (Sigma-Aldrich) for 5 min at 37°C. 
Trypsin was neutralized by 5-fold dilution with complete medium. Cells were 
pelleted by centrifugation at 800g for 5 min at 25°C and washed with 15 mL of 
PBS. The number of cells was determined by a automatic cell counter TC20 (Bio-
Rad). A protein electroporation mixture was prepared by diluting purified [
15
N]-
labelled Cu(I)MNK1 to a final concentration of 500 μM with sterile filtered, 
freshly prepared electroporation buffer (50% 100mM sodium phosphate (pH 7.0), 
5 mM KCl, 15 mM MgCl2,15 mM HEPES, 5 mM ATP, 5 mM reduced 
glutathione). 100μL of the protein electroporation mixture was added to dense 
cells pellet and gently mixed. The 100−200μL cell suspension was transferred into 
electroporation cuvettes (Lonza). Protein electroporation was performed with an 
Amaxa Nucleo-fector (Lonza) by using the pulse program B-28 [88]. Cells were 
pulsed twice while being gently mixed between pulses. Directly after 
electroporation, 1 mL of pre-warmed (37°C) and CO2-saturated complete medium 
was added to each cuvette, the samples were transferred into cell flasks and were 
returned to 5% CO2 incubators. After recovery had proceeded for 4-5 h, non-
adherent cells were removed. Cultures were washed once with PBS (5 mL) and 
harvested by using 0.25% trypsin/EDTA for 5 min, at 37°C. Trypsin was 
neutralized by 5-fold dilution with complete medium, and cells were pelleted by 
centrifugation at 800 g for 5 min at 25°C and washed once with 1 mL of PBS. 
Cell pellets were resuspended in NMR buffer (Leibovitz’s L-15 medium 
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supplemented with 10% FBS) containing 10 % D2O. Cell suspensions were 
transferred into 4mm diameter Shigemi tubes (Shigemi) for NMR analysis. 
4.4. In-cell NMR sample preparation: transient transfection 
HEK293T cells were transiently transfected with the pHLsec plasmid containing 
either the gene of HAH1 or MNK1 through endocytosis mediated by branched 
polyethylenimine (PEI), Sigma. During protein expression, commercial DMEM 
medium was used to prepare unlabeled in-cell NMR samples; the expression 
media were supplemented with 2% FBS and antibiotics. Cells for in-cell NMR 
samples were collected as follows: cells from a 75 cm
2
 flask were detached by 
trypsin treatment and suspended in one cell pellet volume of DMEM medium 
supplemented with 90 mM glucose, 70 mM HEPES buffer and 20% D2O. The cell 
suspension was transferred to a 3 mm Shigemi tube (Shigemi); cells were spun 
down at the bottom of the tube. Cell viability before and after NMR experiments 
remained above 90%, as determined by trypan blue staining. Cleared cell lysates 
were prepared as follows: cells were suspended in one pellet volume of PBS 
buffer supplemented with 0.5 mM EDTA and 4-(2-aminoethyl)-benzenesulfonyl 
fluoride hydrochloride (AEBSF, Sigma) and lysed by freeze-thaw cycles with 
liquid N2 and warm water. The cell lysate was centrifuged (60 min at 16000g, 
4°C) and the cleared supernatant was recovered for NMR analysis in a 3 mm 
standard tube. 
4.5. Cell sample preparation for microscopy 
4.5.1. Immunocytochemistry (ICC) 
Human HEK cells were seeded on coated glass coverslips and transfected with the 
pHLsec plasmid containing either the gene of HAH1 or MNK1 through 
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endocytosis mediated by branched polyethylenimine (PEI). After 48 hours 
expression were washed with PBS and fixed with 4% Paraformaldehyde (PFA) for 
15 minutes at room temperature. 
 
Figure 14.  Optical microscopy on HEK293T cells seeded with the same concentration, upon transfection 
with linear PEI: A) untreated cells; B) cells transiently transfected with HAH1-containing expression vector 
C) cells trasiently transfected with EMPTY expression vector as a control. There is an effect of linear PEI-
mediated transfection treatment that decreases cells viability not depending on the DNA vector. 
For ICC staining, the cells were permeabilized using a PBS buffer containing 
0.1% (v/v) Triton-X. After three washes in PBS, coverslips were blocked with 
blocking buffer 0.13% (v/v) of cold fish skin gelatin in PBS for one hour. 
Meanwhile, a dilution of primary antibody (against either HAH1 or MNK1) was 
made in blocking buffer, in a dilution 1:200. Coverslips were incubated for 2 
hours at RT with the primary antibody, washed thrice with PBS for 5 minutes, 
then incubated with a 1:1000 dilution of the secondary antibody in blocking buffer 
(I used Atto647-coupled anti-Mouse or Atto488-coupled anti-Mouse antibodies). 
adding phalloidin for the actin staining. Cells were incubated with secondary 
antibody and phalloidin for 1 hour, in the dark. Coverslips were washed trice with 
PBS for 5 minutes and then incubated with 2.5 ug/mL DAPI in PBS for 5 minutes 
to stain the nuclei. Coverslips were washed twice with PBS and placed on a drop 
of ImmuMount mountant solution facing down, avoiding trapping air bubbles. 
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Figure 15. Confocal immages of HEK cells. In Cyan DAPI staining for nuclei, in Magenta anti-HAH1 
protein selective antibody, in green Actin staining. A) H22 stable cell line overexpressing HAH1 protein; B) 
HEK293T PEI mediated transient transfected with HAH1-contining expression vector. 
Fluorescence microscopy imaging was performed at Confocal LSM710- 
ConfoCor3 system and Confocal LSM780 system, Zeiss. 
4.6. Polyacrylamide gel electrophoresis (PAGE) 
PAGE is a method that allows the separation of biological macromolecules 
depending on their electrophoretic motility, which is due to their length, 
conformation and charge. It is frequent to treat protein samples with a denaturant 
(sodium dodecyl sulfate, SDS) that makes proteins motility only dependent on 
their length and mass-to-charge ratio. SDS is a anionic detergent able to make 
complexes with proteins resulting in a negative charge that are proportional to the 
protein mass. When exposed to an electric field, the negatively charged 
polypeptides migrate to the anode according to their motility. SDS-PAGE allows 
proteins separation according to their molecular weight. The use of a protein 
marker (prestained or unstained) enable to see the proteins motility in the gel and 
by molecular weight comparison to identify the protein of interest. The 
polyacrylamide gel is consituted of an acrylamide gradient in terms of pH and 
acrylamide concentration. Gradient gels 4-20% mini-PROTEAN
® TGX™precast 
protein gels, BIORAD, were used. The electrophoresis buffer was 25 mM Tris, 
72 
192 mM glycine, 0.1% SDS, pH 8.3. The run took place in mini-PROTEAN
® 
vertical electrophoresis chamber, BIORAD. 
4.7. Western blot (WB) 
Western Blot is a widely used semi-quantitative analytical technique that allows 
the identification and the study of proteins in a matrix throughout specific 
antibodies containing specific epitopes against the protein of interest. Firstly, are 
denatured and separated by size through SDS-PAGE. Secondly, proteins undergo 
an electrotransfer onto a membrane made of nitrocellulose or polyvinylidene 
(PVDF) in order to be accessible to antibody detection. A trans-Blot Turbo, 
BIORAD and PVDF membranes by BIORAD were used for this step. Thirdly, 
blocking of any non-specific binding is achieved by membrane incubation with a 
diluted protein solution, 5% of non fat dry milk in Tris-buffered saline (TBS), 
with a very small percentage of detergent, 0.005% of Tween-20 in TBS 1x. It runs 
1 hour at room temperature (RT) or at 4°C overnight. Fourthly, there is a series of 
incubation steps with a primary antibody and then with a secondary antibody. 
Usually the monoclonal primary antibody incubation lasts two hours, followed by 
three 10-minutes washes with TBS 1x. Then, the peroxidase-coniugated 
secondary antibody incubation goes on for one hour at RT. There is a washing step 
with TBS 1x as previously and finally we have a detection and visualization step. 
A chemiluminescent reaction allows detecting the protein-antibody conjugates; 
EUROCLONE detection Kit was used. The reaction is observed at a 
ChemiDocTMXRS. Chemiluminescence signal intensities were quantified using 
ImageLab software in reference to a calibration curve obtained with recombinant 
protein standards. Equal sample loading was confirmed via GAPDH control. 
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4.7.1. Small scale electroporation  
Small scale electroporation trials tested how starting with different protein 
concentration in the electroporation buffer affected the delivery efficiency inside 
HEK293T cells. In terms of protein concentration in the EP buffer, the plateau is 
reached when the protein is concentrated 0.5 mM and the resulting intracellular 
Cu(I)MNK1 uptake is around 70 µM , as shown in Fig. 16. 
 
Figure 16. Studies of protein delivery in HEK293T cells with electroporation: in A) WB of protein 
Cu(I)MNK1 delivered varying the Cu(I)MNK1 concentration inside the electroporation buffer EP buffer (0.2 
mM, 0.4 mM, 0.5mM), a non-pulsed sample named (-) as pulse effect control, GAPDH was used as a loading 
control and Cu(I)MNK1 purified recombinant protein as standard reference; in B) evaluation of 
[Cu(I)MNK1] uptake inside HEK293T cells respect to the starting concentration of Cu(I)MNK1 in the EP 
buffer, between 0.4mM and 0.6mM the uptake reaches a plateau. 
Empirical data collected over years in Selenko lab showed that the ‘effective’ 
concentration detected inside an in-cell sample by NMR is around 10 times less 
than the value obtained by WB. According to these data, the in-lysate NMR trials 
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were tuned on the putative ‘effective’ MNK1 concentration, which is around 10 
µM.  
4.7.2. In-cell NMR sample: proteins quantification 
The WB quantification of the in-cell NMR sample Cu(I)MNK1 uptake inside the 
cells showed that Cu(I)MNK1 concentration is 67 ±10 µM. In parallel, the 
quantification of HAH1 in the in-cell NMR sample with the stable cell line for 
HAH1 is 110 ±20 µM. Furthermore, after the in-cell NMR sample lysis, I 
analysed separately the soluble fraction from the pellet by WB. The majority of 
the delivered MNK1 was distributed in the soluble fraction. 
4.7.3. HEK293T cells stably transfected with the HAH1 gene: protein 
quantification 
WB was also used to quantify HAH1 concentration inside HEK293T cells stably 
transfected with the HAH1 gene. As shown in Fig. 17, the value obtained is 
100±30 µM. 
 
Figure 17. Protein quantification inside the stable HEK293T cell line transfected for human HAH1. WB 
of stable HEK293T cell line transfected for human HAH1 analysing different amount of cells. GAPDH was 
used as a loading control and HAH1 purified recombinant protein as standard reference. 
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4.8. Solution NMR experiments  
NMR experiments on human cells and their lysates were acquired at a 950 MHz 
Bruker Avance III spectrometer equipped with a TCI CryoProbe. NMR 
experiments on lysates from electroporated cells were acquired at a 900 MHz 
Bruker Avance spectrometer equipped with a TCI Cryoprobe. 1D 
1
H and 2D 
1
H-
15
N SOFAST HMQC [89] spectra were acquired at 308 K. The supernatant of 
each cell sample was checked in the same experimental conditions to exclude the 
presence of any signal arising from protein leaked out of the cells. The same NMR 
spectra were also acquired on the cell lysates. The total acquisition time for each 
cell sample was ~1 h for transiently transfected cells, ~12 h for electroporated cell 
lysates.  
NMR experiments on thick cell lysates and electroporated cell samples were 
acquired at 600 MHz Bruker spectrometer equipped with a TCI CryoProbe. 1D 
1
H 
and 2D 
1
H-
15
N SOFAST HMQC spectra were acquired at 293.8K. The total 
acquisition time for each cell sample was ~16 h.  
In vitro NMR experiments on Cu(I)MNK1 and the Cu(I)MNK1-HAH1 
complex were acquired at a 700 MHz Bruker spectrometer equipped with a TCI 
CryoProbe. The NMR spectra were processed with Bruker Topspin software. 
4.9. Solid state NMR experiments 
E. coli cells were packed into 3.2 mm and 4 mm rotors in order to perform solid 
state NMR experiments. The spectra were recorded on a Bruker Avance 700 MHz 
and on a Bruker Avance II 850 MHz wide-bore spectrometers. Standard 
13
C-
detected solid state NMR spectra were acquired at MAS frequency of 14 kHz or 
11 kHz using the pulse sequences reported in the literature [75]. DCP-NCA solid 
state NMR spectra were acquired at MAS frequency of 14 kHz using the pulse 
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sequences reported in the literature [76]. The 
1
H-
13
C CP NOE solid state NMR 
spectra were acquired at MAS frequency of 14 kHz using the pulse sequences 
reported in the literature [78]. 
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